

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 October 2022 (06.10.2022)



(10) International Publication Number
WO 2022/208430 A1

(51) International Patent Classification:

A61K 39/108 (2006.01) A61P 13/02 (2006.01)

(21) International Application Number:

PCT/IB2022/053013

(22) International Filing Date:

31 March 2022 (31.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

21166781.1 01 April 2021 (01.04.2021) EP

(71) Applicant: **JANSSEN PHARMACEUTICALS, INC.**
[US/US]; 1125 Trenton-Harbourton Road, Titusville, New
Jersey 08560 (US).

(72) Inventors: **WEERDENBURG, Eveline, Marleen**; c/o
Janssen Vaccines & Prevention B.V., Archimedeweg 4-6,
2333 CN Leiden (NL). **GEURTSEN, Jeroen**; c/o Janssen
Vaccines & Prevention B.V., Archimedeweg 4-6, 2333 CN
Leiden (NL). **BURGHOUT, Pieter Jan**; c/o Janssen Vac-
cines & Prevention B.V., Archimedeweg 4-6, 2333 CN Lei-
den (NL).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: PRODUCTION OF E. COLI O18 BIOCONJUGATES

(57) Abstract: The invention pertains to host cells for producing a bioconjugate of an *E. coli* O18 antigen polysaccharide conjugated to a carrier protein. The host cells are characterized in that they comprise modified Wzy O-antigen polymerases with specific combinations of amino acid substitutions in one or more of positions 199, 377 and 395 as compared to the wild type Wzy O- antigen polymerase of SEQ ID NO: 1, which modified Wzy O-antigen polymerases improve the yield and glycosylation pattern of the O18 bioconjugates produced by the host cells. The invention further relates to methods wherein the host cells are used to produce a bioconjugate of an *E. coli* O18 antigen polysaccharide conjugated to a carrier protein, compositions comprising these bioconjugates, including multivalent compositions comprising bioconjugates of additional O antigen polysaccharide-serotypes.



WO 2022/208430 A1

PRODUCTION OF *E. COLI* O18 BIOCONJUGATES

FIELD OF THE INVENTION

This invention relates to the fields of medical microbiology, immunology and vaccines. In particular the invention relates to host cells comprising improved Wzy O-antigen polymerases for producing bioconjugates of *E. coli* O18 antigen polysaccharide with an increased yield and increased degree of glycosylation. The invention further relates to compositions comprising the bioconjugates of the invention and to the use of such compositions for inducing an immune response against *E. coli* for the prevention or treatment of *E. coli* infections, in particular infections with invasive extra-intestinal pathogenic *E. coli* (ExPEC) disease.

BACKGROUND OF THE INVENTION

Extraintestinal pathogenic *Escherichia coli* (ExPEC) strains are normally harmless inhabitants of the human gastrointestinal tract, alongside commensal *E. coli* strains. ExPEC isolates cannot readily be distinguished from commensal isolates by serotype, although many clonal lineages are dominated by ExPEC, as defined by O-antigen, capsule and flagellar antigen serotypes (abbreviated as O:K:H, for example O25:K1:H4). In contrast to commensal *E. coli*, ExPEC strains express a broad array of virulence factors enabling them to colonize the gastrointestinal tract, as well as to cause a wide range of extraintestinal infections, which are associated with a significant healthcare cost burden due to hospitalization and death. Neonates, the elderly, and immunocompromised patients are particularly susceptible to ExPEC infection, including invasive ExPEC disease (IED).

The O-antigen comprises the immunodominant component of the cell wall lipopolysaccharide (LPS) in Gram-negative bacteria, including *E. coli*. There are currently >180 serologically unique *E. coli* O-antigens identified, with the vast majority of ExPEC isolates classified within less than 20 O-antigen serotypes. Full-length *E. coli* O-antigens are typically comprised of about 10 to 25 repeating sugar units attached to the highly conserved LPS core structure, with each component synthesized separately by enzymes encoded predominantly in the *rfb* and *rfa* gene clusters, respectively. Following polymerization of the O-antigen, the O-antigen polysaccharide backbone may be modified, typically through the addition of acetyl or glucose residues. These modifications effectively increase serotype diversity by creating antigenically distinct serotypes that share a common polysaccharide backbone, but differ in side branches. Genes encoding O-antigen modifying enzymes typically reside outside of the *rfb* cluster on the chromosome, and in some cases, these genes are found within lysogenic bacteriophages.

Efforts toward the development of a vaccine to prevent ExPEC infections have focused on O-antigen polysaccharide conjugates. A 12-valent O-antigen conjugate vaccine was synthesized through extraction and purification of O-antigen polysaccharide and chemical conjugation to detoxified *Pseudomonas aeruginosa* exotoxin A and tested for safety and immunogenicity in a Phase 1 clinical study (Cross et al., J. Infect. Dis. (1994) v.170, pp.834-40). This candidate vaccine

was never licensed for clinical use. A bioconjugation system in *E. coli* has been developed recently, in which the antigen polysaccharide and the carrier protein are both synthesized *in vivo* and subsequently conjugated *in vivo* through the activities of the oligosaccharyl transferase PglB, a *Campylobacter jejuni* enzyme, expressed in *E. coli* (Wacker et al., Proc. Nat. Acad. Sci. (2006) v. 103, pp. 7088-93). This N-linked protein glycosylation system is capable of the transfer of diverse polysaccharides to a carrier protein, allowing for methods to purify the bioconjugate from bacteria wherein it is expressed. Bioconjugation has been used successfully to produce conjugate polysaccharide for an *E. coli* four-valent O-antigen candidate vaccine (Poolman and Wacker, J. Infect. Dis. (2016) v.213(1), pp. 6-13; WO 2015/124769; WO 2017/035181).

A composition comprising 10 bioconjugates (O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B and O75, the composition being referred to as ExPEC10V) has been described and is in clinical trials (e.g. WO2020/191082A1).

It was observed that the product yield for bioconjugates with O18A antigen polysaccharide was lowest compared to the other nine bioconjugates prepared for ExPEC10V (WO2020/191082A1). Furthermore, the O18A bioconjugate so produced appeared to contain a relatively high amount of glycans made up of a limited number of O18A antigen polysaccharide repeat units, referred to as 'sEPA' (i.e. EPA carrier protein having polysaccharide chains with only about 1-3 repeat units, which amounted to more than 20% of the O18A bioconjugates in the periplasmic fraction in the production process for the O18A bioconjugate drug substance), which sEPA product is not easily separated from the preferred bioconjugate that comprises mainly glycans wherein the O18A antigen polysaccharide is made up of at least five repeat units. ExPEC isolates belonging to the O18 serogroup have been commonly identified in contemporary surveillance studies of U.S. and EU blood isolates, and O18 conjugates are therefore deemed to be a relevant component of an ExPEC vaccine. Improving the yields of conjugates of O18 antigen polysaccharide would therefore be desired.

It is thus an object of the invention to provide for materials and methods for increasing the product yield of bioconjugates comprising O18 antigen polysaccharide during production and/or to produce materials and methods for obtaining O18 bioconjugates with decreased relative amounts of sEPA as compared to O18 bioconjugates obtained using a previously described production process. It is another object of the invention to provide for materials and methods for producing bioconjugates of *E. coli* O18A antigen polysaccharide with an increased degree of glycosylation as compared to O18 bioconjugates obtained using materials and methods as previously described.

SUMMARY OF THE INVENTION

In a first aspect, the invention relates to a gram-negative bacterial host cell comprising: (a) a carrier protein comprising at least one glycosylation consensus sequence; (b) an *E. coli* O18 *rffB* locus; and, (c) an oligosaccharyltransferase; wherein the cell comprises a polypeptide having Wzy O-antigen polymerase activity, which polypeptide comprises an amino acid sequence with at least 95% identity with SEQ ID NO: 1, wherein the amino acid sequence comprises: i) isoleucine (Ile, I) at a position that corresponds to position 199 in SEQ ID NO: 1, lysine (Lys, K) at a position that

corresponds to position 377 in SEQ ID NO: 1 and alanine (Ala, A) at a position that corresponds to position 395 in SEQ ID NO: 1; ii) threonine (Thr, T) at a position that corresponds to position 199 in SEQ ID NO: 1, lysine at a position that corresponds to position 377 in SEQ ID NO: 1 and valine (Val, V) at a position that corresponds to position 395 in SEQ ID NO: 1; iii) threonine at a position that corresponds to position 199 in SEQ ID NO: 1, lysine at a position that corresponds to position 377 in SEQ ID NO: 1 and alanine at a position that corresponds to position 395 in SEQ ID NO: 1; iv) isoleucine at a position that corresponds to position 199 in SEQ ID NO: 1, lysine at a position that corresponds to position 377 in SEQ ID NO: 1 and valine at a position that corresponds to position 395 in SEQ ID NO: 1; or v) isoleucine at a position that corresponds to position 199 in SEQ ID NO: 1, methionine (Met, M) at a position that corresponds to position 377 in SEQ ID NO: 1 and alanine at a position that corresponds to position 395 in SEQ ID NO: 1.

In one embodiment, in the host cell, the polypeptide having Wzy O-antigen polymerase activity comprises the amino acid sequence of SEQ ID NO: 1, except that the amino acid sequence comprises: i) Ile at position 199, Lys at position 377 and Ala at position 395; ii) Thr at position 199, Lys at position 377 and Val at position 395; iii) Thr at position 199, Lys at position 377 and Ala at position 395; iv) Ile at position 199, Lys at position 377 and Val at position 395; or v) Ile at position 199, Met at position 377 and Ala at position 395; wherein all positions are corresponding to those in SEQ ID NO: 1.

In one embodiment, in the host cell, the polypeptide having Wzy O-antigen polymerase activity comprises Ile at position 199, Lys at position 377 and Ala at position 395, wherein the positions correspond to those in SEQ ID NO: 1.

In one embodiment, the host cell comprises a polynucleotide or vector encoding the polypeptide having Wzy O-antigen polymerase activity is integrated into the genome of the host cell.

In one embodiment, the host cell is an *Escherichia coli* host cell. In a preferred embodiment, the host cell is an *E. coli* K-12 strain, more preferably *E. coli* K-12 strain W3110.

In one embodiment, in the host cell, at least one of: a) the oligosaccharyl transferase comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 6; b) the carrier protein comprises SEQ. ID NO. 3; and, c) the *E. coli* O18 *rff* locus is an *rff* locus of an *E. coli* strain having serotype O18A. Preferably, the oligosaccharyl transferase comprises the amino acid sequence of SEQ ID NO: 6.

In one embodiment, the host cell comprises an *E. coli* O18 *rff* locus with a nucleotide sequence encoding a Wzy O-antigen polymerase that encodes a polypeptide having Wzy O-antigen polymerase activity as defined herein above.

In a further aspect, the invention pertains to a method for producing a bioconjugate of an *E. coli* O18 antigen polysaccharide conjugated to a carrier protein, the method comprising: (a) culturing a host cell of the invention as defined herein above, to produce the bioconjugate. Preferably, the method further comprises recovery of the bioconjugate.

In one embodiment, the method further comprises formulating the recovered bioconjugate into a pharmaceutical composition.

In one embodiment, the method further comprises adding one or more additional bioconjugates of *E. coli* O-antigen polysaccharides conjugated to a carrier protein to the pharmaceutical composition to obtain a multivalent bioconjugate composition. Preferably, the one or more additional bioconjugates comprise at least one O-antigen polysaccharide selected from the group consisting of *E. coli* serotypes O1, O2, O4, O6, O8, O15, O16, O25 and O75. In a preferred embodiment, the multivalent bioconjugate composition produced in the method comprises: (i) the bioconjugate of an *E. coli* O18A antigen polysaccharide conjugated to a carrier protein; (ii) a bioconjugate of an *E. coli* O1A antigen polysaccharide conjugated to a carrier protein; (iii) a bioconjugate of an *E. coli* O2 antigen polysaccharide conjugated to a carrier protein; (iv) a bioconjugate of an *E. coli* glucosylated O4 antigen polysaccharide conjugated to a carrier protein; (v) a bioconjugate of an *E. coli* O6A antigen polysaccharide conjugated to a carrier protein; (vi) a bioconjugate of an *E. coli* O15 antigen polysaccharide conjugated to a carrier protein; (vii) a bioconjugate of an *E. coli* O16 antigen polysaccharide conjugated to a carrier protein; (viii) a bioconjugate of an *E. coli* O25B antigen polysaccharide conjugated to a carrier protein; and, (ix) a bioconjugate of an *E. coli* O75 antigen polysaccharide conjugated to a carrier protein, wherein preferably the carrier protein in each bioconjugate comprises SEQ ID NO: 3. In a more preferred embodiment, the multivalent bioconjugate composition produced in the method further comprises: (x) a bioconjugate of an *E. coli* O8 antigen polysaccharide conjugated to a carrier protein, wherein preferably the carrier protein comprises SEQ ID NO: 3.

DESCRIPTION OF THE FIGURE

Fig. 1. Coomassie-stained SDS-PAGE loaded with periplasmic extracts from shake flask cultures of *E. coli* production strain W3110 for O18A bioconjugates containing Wzy variants with SEQ ID NO: 1 (lane 1 and 3) or with amino acid substitutions 199I, 377K, 395A (lane 2 and 4) that were induced for O18A polysaccharide bioconjugate expression. In samples loaded on lanes 1 and 2 the oligosaccharyl transferase enzyme PglB was expressed from a size-reduced expression plasmid whereas in lane 3 and 4 the vector backbone of the PglB expression plasmid contained an additional 4500 bp of DNA sequence, comprising non-coding DNA and the lac repressor gene lacI, which appeared optimal for product expression. Bands showing O18A polysaccharide bioconjugate material are indicated with arrows, depicting the approximate size of mono-glycosylated EPA (M), di-glycosylated EPA (D) and tri-glycosylated EPA (T).

DESCRIPTION OF THE INVENTION

Unless defined otherwise, all technical and scientific terms used herein have the same meaning commonly understood to one of ordinary skill in the art to which this invention pertains. Otherwise, certain terms cited herein have the meanings as set in the specification. All patents, published patent applications and publications cited herein are incorporated by reference as if set

forth fully herein. It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise.

Throughout this description and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integer or step. When used herein the term "comprising" can be substituted with the term "containing" or "including" or sometimes when used herein with the term "having".

When used herein "consisting of" excludes any element, step, or ingredient not specified in the claim element. When used herein, "consisting essentially of" does not exclude materials or steps that do not materially affect the basic and novel characteristics of the claim. Any of the aforementioned terms of "comprising", "containing", "including", and "having", whenever used herein in the context of an aspect or embodiment of the invention can be replaced with the term "consisting of" or "consisting essentially of" to vary scopes of the disclosure.

As used herein, the conjunctive term "and/or" between multiple recited elements is understood as encompassing both individual and combined options. For instance, where two elements are conjoined by "and/or", a first option refers to the applicability of the first element without the second. A second option refers to the applicability of the second element without the first. A third option refers to the applicability of the first and second elements together. Any one of these options is understood to fall within the meaning, and therefore satisfy the requirement of the term "and/or" as used herein. Concurrent applicability of more than one of the options is also understood to fall within the meaning, and therefore satisfy the requirement of the term "and/or."

The word "about" or "approximately" when used in association with a numerical value means that the value may be the given value plus or minus 20% of the value, preferably plus or minus 10% of the value, more preferably plus or minus 5% of the value.

Sequence identity is herein defined as a relationship between two or more amino acid (polypeptide or protein) sequences or two or more nucleic acid (polynucleotide) sequences, as determined by comparing the sequences. "Similarity" between two amino acid sequences is determined by comparing the amino acid sequence and its conserved amino acid substitutes of one polypeptide to the sequence of a second polypeptide. "Identity" and "similarity" can be readily calculated by known methods.

"Sequence identity" and "sequence similarity" can be determined by alignment of two peptide or two nucleotide sequences using global or local alignment algorithms, depending on the length of the two sequences. Sequences of similar lengths are preferably aligned using a global alignment algorithm (e.g. Needleman Wunsch) which aligns the sequences optimally over the entire length, while sequences of substantially different lengths are preferably aligned using a local alignment algorithm (e.g. Smith Waterman). Sequences may then be referred to as "substantially identical" or "essentially similar" when they (when optimally aligned by for example the programs GAP or BESTFIT using default parameters) share at least a certain minimal percentage of sequence

identity (as defined below). Most preferably, sequence alignments are performed in a ClustalW (1.83) sequence alignment using default settings.

Alternatively, percentage similarity or identity may be determined by searching against public databases, using algorithms such as FASTA, BLAST, etc. Thus, the nucleic acid and protein sequences of the present invention can further be used as a “query sequence” to perform a search against public databases to, for example, identify other family members or related sequences. Such searches can be performed using the BLASTn and BLASTx programs (version 2.0) of Altschul, et al. (1990) J. Mol. Biol. 215:403—10. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to wzy nucleic acid molecules of the invention. BLAST protein searches can be performed with the BLASTx program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., (1997) Nucleic Acids Res. 25(17): 3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., BLASTx and BLASTn) can be used. See the homepage of the National Center for Biotechnology Information at <http://www.ncbi.nlm.nih.gov/>.

Unless otherwise indicated, the term “at least” preceding a series of elements is to be understood to refer to every element in the series.

20 DETAILED DESCRIPTION OF THE INVENTION

The inventors of present application have surprisingly found that the use of a Wzy O-antigen polymerase that differs from the reference sequence at one or more specific positions led to a significant improvement of the production yield of O18 antigen polysaccharide bioconjugate. In addition, the use of such polymerase was found to surprisingly facilitate the production of an O18 antigen polysaccharide conjugate with an increased glycan to protein ratio and/or increased occupancy of glycosylation sites.

Accordingly, in a first aspect, the invention provides a host cell for use in producing a bioconjugate of an *E. coli* O18 antigen polysaccharide conjugated to a carrier protein.

In one embodiment, a host cell of the invention at least comprises: (a) a carrier protein comprising at least one glycosylation consensus sequence; (b) an *E. coli* O18 *rfb* locus; (c) an oligosaccharyltransferase; and, (d) a polypeptide of the invention having Wzy O-antigen polymerase activity.

In the host cell, the polypeptide of the invention having Wzy O-antigen polymerase activity is a polypeptide comprising an amino acid sequence that has at least 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% amino acid sequence identity with the amino acid sequence of SEQ ID NO: 1, and further having O-antigen polymerase activity. Whether or not a polypeptide of the invention has O-antigen polymerase activity can be assayed by expressing a nucleotide sequence encoding the Wzy O-antigen polymerase in a suitable host cell and determining the amount of polymerized O-antigen produced by methods known to the person skilled in the art or for example as described in

Woodward et al. (2010, Nat Chem Biol. 2010 Jun; 6(6): 418–423), which is herein incorporated in its entirety.

In one embodiment, a host cell of the invention comprises a polypeptide having Wzy O-antigen polymerase activity, which polypeptide comprises an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identity with SEQ ID NO: 1, wherein the amino acid sequence comprises:

i) isoleucine at a position that corresponds to position 199 in SEQ ID NO: 1, lysine at a position that corresponds to position 377 in SEQ ID NO: 1 and alanine at a position that corresponds to position 395 in SEQ ID NO: 1;

10 ii) threonine at a position that corresponds to position 199 in SEQ ID NO: 1, lysine at a position that corresponds to position 377 in SEQ ID NO: 1 and valine at a position that corresponds to position 395 in SEQ ID NO: 1;

15 iii) threonine at a position that corresponds to position 199 in SEQ ID NO: 1, lysine at a position that corresponds to position 377 in SEQ ID NO: 1 and alanine at a position that corresponds to position 395 in SEQ ID NO: 1;

iv) isoleucine at a position that corresponds to position 199 in SEQ ID NO: 1, lysine at a position that corresponds to position 377 in SEQ ID NO: 1 and valine at a position that corresponds to position 395 in SEQ ID NO: 1; or,

20 v) isoleucine at a position that corresponds to position 199 in SEQ ID NO: 1, methionine at a position that corresponds to position 377 in SEQ ID NO: 1 and alanine at a position that corresponds to position 395 in SEQ ID NO: 1.

An amino acid position that corresponds to one of amino acid positions 199, 377 or 395 in SEQ ID NO: 1, respectively, is herein understood to refer to a position in an amino acid sequence other than SEQ ID NO: 1 that aligns with one of the positions 199, 377 or 395 in SEQ ID NO: 1, respectively, in a sequence alignment of SEQ ID NO: 1 with that sequence other than SEQ ID NO: 1, preferably in a ClustalW (1.83) sequence alignment with SEQ ID NO: 1, preferably using default settings. The skilled person will know how to identify corresponding amino acid positions in Wzy O-antigen polymerase amino acid sequences other than SEQ ID NO: 1 using amino acid sequence alignment algorithms as defined herein.

30 In a preferred embodiment, a host cell of the invention comprises a polypeptide having Wzy O-antigen polymerase activity, which polypeptide comprises the amino acid sequence of SEQ ID NO: 1, except that the amino acid sequence comprises: i) isoleucine at a position that corresponds to position 199 in SEQ ID NO: 1, lysine at a position that corresponds to position 377 in SEQ ID NO: 1, and alanine at a position that corresponds to position 395 in SEQ ID NO: 1; ii) threonine at a position that corresponds to position 199 in SEQ ID NO: 1, lysine at a position that corresponds to position 377 in SEQ ID NO: 1, and valine at a position that corresponds to position 395 in SEQ ID NO: 1; iii) threonine at a position that corresponds to position 199 in SEQ ID NO: 1, lysine at a position that corresponds to position 377 in SEQ ID NO: 1, and alanine at a position that corresponds to position 395 in SEQ ID NO: 1; iv) isoleucine at a position that corresponds to position

199 in SEQ ID NO: 1, lysine at a position that corresponds to position 377 in SEQ ID NO: 1, and valine at a position that corresponds to position 395 in SEQ ID NO: 1; or v) isoleucine at a position that corresponds to position 199 in SEQ ID NO: 1, methionine at a position that corresponds to position 377 in SEQ ID NO: 1, and alanine at a position that corresponds to position 395 in SEQ ID NO: 1. Thus, in this embodiment the host cell of the invention comprises a polypeptide having Wzy O-antigen polymerase activity, which polypeptide comprises the amino acid sequence of SEQ ID NO: 1, except that the amino acid sequence comprises: i) isoleucine at position 199 in SEQ ID NO: 1, lysine at position 377 in SEQ ID NO: 1 and alanine at position 395 in SEQ ID NO: 1; ii) lysine at position 377 in SEQ ID NO: 1; iii) lysine at position 377 in SEQ ID NO: 1 and alanine at position 395 in SEQ ID NO: 1; iv) isoleucine at position 199 in SEQ ID NO: 1 and lysine at position 377 in SEQ ID NO: 1; or, v) isoleucine at position 199 in SEQ ID NO: 1 and alanine at position 395 in SEQ ID NO: 1.

In a particularly preferred embodiment, a host cell of the invention comprises a polypeptide having Wzy O-antigen polymerase activity, which polypeptide comprises, isoleucine at a position that corresponds to position 199 in SEQ ID NO: 1, lysine at a position that corresponds to position 377 in SEQ ID NO: 1, and alanine at a position that corresponds to position 395 in SEQ ID NO: 1.

As will be understood by the skilled person, in one embodiment, for expression of a polypeptide having Wzy O-antigen polymerase activity, a host cell of the invention will preferably comprise a polynucleotide encoding the polypeptide having Wzy O-antigen polymerase activity of the invention as defined herein above. The polynucleotide may be preceded by a promoter operably linked thereto. In certain embodiments, the promoter is endogenous to the Wzy O-antigen polymerase coding sequence. In certain preferred embodiments, the promoter is an endogenous promoter driving the expression of Wzy O-antigen polymerase in a bacterium of the Enterobacteriaceae family, preferably a bacterium of the genus *Escherichia*, more preferably a bacterium of the species *E. coli*. In other embodiments, the promoter is heterologous to the Wzy coding sequence e.g. a strong promoter known to the skilled person for use in recombinant expression systems is used. For example, the promoter is an inducible or constitutive prokaryotic promoter, such as an ara, phoA, tac, tet, trc, trp, PBAD, λ PL, T5, or T7 promoter.

In certain embodiments, the invention provides an isolated polynucleotide that can be used in the construction of a host cell according to the invention. The polynucleotide can be a recombinant, synthetic or artificial polynucleotide. The polynucleotide may be in any form of nucleic acid, e.g. DNA or RNA, preferably DNA. The polynucleotide may comprise one or more nucleotides that are not present in a naturally occurring Wzy encoding polynucleotide, such as the naturally occurring Wzy encoding polynucleotide of SEQ ID NO: 2. Specifically, the polynucleotide for use in the invention will at least differ from a naturally occurring Wzy encoding polynucleotide such as SEQ ID NO: 2 in one or more of the codons corresponding to the positions 199, 377 and 395 in SEQ ID NO: 1. In addition the polynucleotide for use in the invention can differ from a naturally occurring Wzy encoding polynucleotide in codons other than the positions corresponding to at least one of the positions 199, 377 and 395 in SEQ ID NO:1. The polynucleotide may have one or more

nucleotides that are not present in a naturally occurring Wzy-encoding polynucleotide at its 5'-end and/or 3'-end. Skilled persons may, using routine techniques, make nucleotide substitutions that do not affect the polypeptide sequence encoded by the polynucleotides described to reflect the codon usage of any particular host organism in which the polypeptides are to be expressed. Therefore, unless otherwise specified, a "nucleotide sequence encoding an amino acid sequence" includes all nucleotide sequences that are degenerate versions of each other and that encode the same amino acid sequence.

As will further be understood by the skilled person, in one embodiment, the polynucleotide encoding the polypeptide having Wzy O-antigen polymerase activity of the invention as defined herein above may be comprised in an expression construct or vector. Preferably in the expression construct the polynucleotide encoding the polypeptide having Wzy O-antigen polymerase activity is operably linked to expression control sequence for expression of the polypeptide in the host cell of the invention, e.g. in an expression cassette. Such expression control sequence can include a promoter as specified above and can further include a Shine–Dalgarno sequence, a transcription termination sequence, etc., etc. In one embodiment, expression construct is comprised in a vector. In one embodiment, the vector is an episomal vector, such as a plasmid or a viral vector, preferably a plasmid. In another embodiment, the polynucleotide, the vector, or the expression construct is integrated into the genome of the host cell. In certain embodiments, the vector or expression construct is preferably in the form of DNA. In certain embodiments, the vector comprises the polynucleotide of the invention operably linked to a promoter, meaning that the polynucleotide is under control of a promoter. In certain embodiments, the polynucleotide encoding the polypeptide having Wzy O-antigen polymerase activity of the invention as defined herein is integrated into its natural position in the *rfb* locus in the genome of the host cell, for instance created by site-directed mutagenesis, using homologous recombination-based genetic modification techniques, which are known to the person skilled in the art of molecular biology.

The host cell of the invention for use in producing a bioconjugate of an *E. coli* O18 antigen polysaccharide conjugated to a carrier protein, is a bacterial host cell. In one embodiment, the host cell is a gram-negative bacterial host cell. Suitable bacterial or prokaryotic host cells for use in producing a bioconjugate comprising an *E. coli* O18 antigen, include, but are not limited to, *Escherichia* species, *Shigella* species, *Klebsiella* species, *Xhantomonas* species. *Salmonella* species. *Yersinia* species, *Lactococcus* species, *Lactobacillus* species. *Pseudomonas* species, *Corynebacterium* species, *Streptomyces* species. *Streptococcus* species. *Staphylococcus* species. *Bacillus* species, and *Clostridium* species. In a preferred embodiment, the host cell of the invention is an *Escherichia coli* host cell, more preferably an *E. coli* K-12 strain, such as strain W3110, the latter being particularly preferred.

In one embodiment, the host cell is a non-naturally occurring host cell. Thus, the host cell may be derived from a naturally occurring isolate, e.g. a clinical isolate, which has been modified to express a polypeptide having Wzy O-antigen polymerase activity as described herein and, which preferably has been further modified to comprise one or more or all of i) an O18 *rfb* locus as herein

defined, ii) (a nucleic acid construct for expression of) a carrier protein comprising at least one glycosylation consensus sequence as herein defined, and iii) (a nucleic acid construct for expression of) an oligosaccharyl transferase as herein defined.

5 The host cell of the invention for use in producing a bioconjugate of an *E. coli* O18 antigen polysaccharide conjugated to a carrier protein further preferably comprises an oligosaccharyl transferase (OST) for transfer of oligosaccharides to N-glycosylation sites on the carrier protein. Preferably therefore, a host cell as herein provided comprises a nucleotide sequence encoding an oligosaccharyl transferase (OST). Oligosaccharyl transferases as used herein are enzymes that transfer lipid-linked oligosaccharides to residues of nascent polypeptide chains that comprise a glycosylation consensus motif, for example to asparagine (Asn, N) residues of nascent polypeptide chains that comprise an N-glycosylation consensus motif, examples of such N-glycosylation consensus motifs being SEQ ID NO: 4 or Asn-X-Ser(Thr). Throughout this application it is to be understood that for the N-glycosylation motif Asn-X-Ser(Thr), X can be any amino acid except proline. Preferably such oligosaccharyl transferases transfer the oligosaccharides to asparagine residues of SEQ ID NO: 4 in a polypeptide chain of a carrier protein as described herein. The nucleic acid that encodes an oligosaccharyl transferase can be native to the host cell, or can be introduced into the host cell using genetic approaches. In preferred embodiments, the oligosaccharyl transferase is heterologous to the host cell. *E. coli* does not naturally comprise an oligosaccharyl transferase, and hence if *E. coli* is used as a host cell for production of bioconjugates, a heterologous oligosaccharyl transferase is comprised in such host cell, e.g. upon introduction by genetic engineering. The oligosaccharyl transferase can be from any source known in the art in view of the present disclosure.

15 In certain preferred embodiments, the oligosaccharyl transferase is an oligosaccharyl transferase from *Campylobacter*. For example, in one embodiment, the oligosaccharyl transferase is an oligosaccharyl transferase from *Campylobacter jejuni* (i.e., PglB; see, e.g., Wacker et al., 2002, Science 298:1790-1793; see also, e.g., NCBI Gene ID: 3231775, UniProt Accession No. O86154). In another embodiment, the oligosaccharyl transferase is an oligosaccharyl transferase from *Campylobacter lari* (see, e.g., NCBI Gene ID: 7410986).

20 In specific embodiments, the oligosaccharyl transferase is PglB from *Campylobacter jejuni*, including the natural (wild-type) protein or any variant thereof, such as those described in International Patent Application Publications WO 2016/107818 and WO 2016/107819. PglB can transfer lipid-linked oligosaccharides to asparagine residues in the consensus sequences SEQ ID NO: 4 and Asn-X-Ser(Thr). In particular embodiments, the PglB oligosaccharyl transferase is a polypeptide having oligosaccharyl transferase as defined herein, which polypeptide comprises an amino acid sequence with at least 80, 85, 90, 95, 96, 97, 98 or 99% sequence identity to SEQ ID NO: 6. In a preferred embodiment, the PglB oligosaccharyl transferase comprises an amino acid sequence that is identical to SEQ ID NO: 6. In certain embodiments one or more endogenous glycosylation consensus sequences in a wild-type PglB have been mutated to avoid PglB autoglycosylation, e.g. SEQ ID NO: 6 comprising the mutation N534Q. Examples of variant PglB

suitable for use in the host cell provided herein include the PglB of SEQ ID NO: 6 comprising the mutation N311V.

The host cell of the invention for use in producing a bioconjugate of an *E. coli* O18 antigen polysaccharide conjugated to a carrier protein further preferably comprises a nucleotide sequence
5 encoding a carrier protein comprising at least one glycosylation site comprising a glycosylation consensus sequence Asn-X-Ser(Thr), more preferably at least one glycosylation site having SEQ ID NO: 4.

In some embodiments, the carrier protein is selected from the group consisting of detoxified Exotoxin A of *P. aeruginosa* (EPA), *E. coli* flagellin (FliC), CRM197, maltose binding protein (MBP),
10 Diphtheria toxoid, Tetanus toxoid, detoxified hemolysin A of *S. aureus*, clumping factor A, clumping factor B, *E. coli* heat labile enterotoxin, detoxified variants of *E. coli* heat labile enterotoxin, Cholera toxin B subunit (CTB), cholera toxin, detoxified variants of cholera toxin, *E. coli* Sat protein, the passenger domain of *E. coli* Sat protein, *Streptococcus pneumoniae* Pneumolysin, Keyhole limpet hemocyanin (KLH), *P. aeruginosa* PcrV, outer membrane protein of *Neisseria meningitidis* (OMPC),
15 and protein D from non-typeable *Haemophilus influenzae*.

In certain embodiments, the carrier protein is detoxified exotoxin A of *Pseudomonas aeruginosa* (EPA), or CRM197, preferably the carrier protein is EPA. For EPA, various detoxified protein variants have been described in literature and could be used as carrier proteins. In certain
20 embodiments, the EPA carrier proteins used in the conjugates of the invention are modified in such a way that the protein is less toxic and/or more susceptible to glycosylation. For example, detoxification can be achieved by mutating and deleting the catalytically essential residues L552V and ΔE553 according to Lukac et al., 1988, Infect Immun, 56: 3095-3098, and Ho et al., 2006, Hum Vaccin, 2:89-98. In a specific embodiment, the carrier proteins used in the generation of the
25 conjugates of the invention are modified such that the number of glycosylation sites in the carrier proteins is optimized in a manner that allows for lower concentrations of the protein to be administered, e.g., in an immunogenic composition, in its bioconjugate form. In a particular embodiment, the host cell encodes EPA comprising 1-10, preferably 2-4, preferably 4 glycosylation sites comprising a glycosylation consensus sequence having SEQ ID NO: 4. In one embodiment, the carrier protein comprises an amino acid sequence with at least 80, 85, 90, 95, 96, 97, 98 or
30 99% sequence identity to SEQ ID NO: 3, and comprises 1-10, preferably 2-4, preferably 4 glycosylation sites comprising a glycosylation consensus sequence Asn-X-Ser(Thr), more preferably having SEQ ID NO: 4. In a preferred embodiment, the carrier protein comprises EPA that comprises the amino acid sequence of SEQ ID NO: 3.

In certain preferred embodiments, the host cell according to the invention comprises a
35 nucleotide sequence encoding the oligosaccharyl transferase comprising SEQ ID NO: 6 and a nucleotide sequence encoding the carrier protein comprising SEQ ID NO: 3.

The host cell of the invention for use in producing a bioconjugate of an *E. coli* O18 antigen polysaccharide conjugated to a carrier protein further preferably comprises an *E. coli* O18 *rfb* locus for synthesis of an O18-antigen polysaccharide structure.

In *E. coli*, the gene products involved in O-antigen biogenesis are encoded by the *rfb* locus. The host cell as herein provided thus further preferably comprises a nucleotide sequence of an *E. coli* O18 *rfb* locus, preferably an *rfb* locus of an *E. coli* strain having serotype O18A. As used herein, "O18 *rfb* locus" and "O18 *rfb* gene cluster" refer to a locus in the gram-negative bacterial genome
5 that comprises a cluster of genes that together encode the enzymatic machinery capable of synthesizing an O18-antigen polysaccharide structure. The term *rfb* locus preferably refers to a genomic locus from the genus *Escherichia*, particularly *E. coli*.

In certain embodiments, the O18 *rfb* locus is heterologous to the host cell, e.g. introduced into a precursor cell of the host cell, and preferably integrated into the genome thereof. Preferably
10 an original *rfb* gene cluster, if such was present in a precursor cell, has been replaced by the O18 *rfb* gene cluster in the host cell, to enable production of bioconjugate of O18.

In certain embodiments, the *rfb* gene cluster for the *E. coli* O18 antigen polysaccharide is an *rfb* gene cluster for the *E. coli* O18A antigen polysaccharide. Thus, preferably, an *rfb* gene cluster for the *E. coli* O18A antigen polysaccharide comprises a nucleotide sequence that is at least 80,
15 85, 90, 95, 96, 97, 98 or 99% identical to SEQ ID NO: 5, which nucleotide sequence encodes the enzymes that create the *E. coli* O18A antigen polysaccharide and wherein preferably the nucleotide sequence encoding the Wzy O-antigen polymerase is a nucleotide sequence encoding the polypeptide having Wzy O-antigen polymerase activity of the invention, as herein defined above. In certain embodiments the *rfb* gene cluster comprises the nucleotide sequence of SEQ ID NO: 5 with
20 the exception of the sequence encoding the Wzy O-antigen polymerase, which is a nucleotide sequence encoding the polypeptide having Wzy O-antigen polymerase activity of the invention, as herein defined above. The structure of the repeat unit for *E. coli* O18A antigen polysaccharide is shown as entry (O18A) in Table 1.

Thus, in certain preferred embodiments, a host cell of the invention comprises an *E. coli rfb*
25 gene cluster wherein the nucleotide sequence encoding a Wzy O-antigen polymerase is a nucleotide sequence that encodes a polypeptide having Wzy O-antigen polymerase activity of the invention, as herein defined above. Therefore, in certain preferred embodiments, the endogenous Wzy O-antigen polymerase coding sequence has been replaced by a nucleotide sequence encoding a polypeptide having Wzy O-antigen polymerase activity of the invention the Wzy
30 polymerase of the invention, as herein defined above. Removal of the endogenous Wzy coding sequences and replacement with a sequence coding for a Wzy polymerase of the invention can be achieved by using gene editing techniques as are commonly known in the art.

In one embodiment, the *waaL* gene is deleted from or functionally inactivated in the genome of a host cell of the invention. The terms "*waaL*" and "*waaL* gene" refer to the O-antigen ligase gene
35 encoding a membrane bound enzyme with an active site located in the periplasm. The *waaL* gene encoded enzyme transfers undecaprenylphosphate (UPP)-bound O antigen to the lipid A core, forming lipopolysaccharide. Deletion or disruption of the endogenous *waaL* gene (e.g., $\Delta waaL$ strains) disrupts transfer of the O-antigen to lipid A, and can instead enhance transfer of the O-

antigen to another available biomolecule, such as a carrier protein expressed in a host cell of the invention.

In one embodiment of a host cell of the invention, the *E. coli gtrABS* genes, which are responsible for O16 O-antigen glucosylation, are deleted from or functionally inactivated in the host cell's genome. In a preferred embodiment, the *E. coli gtrABS* genes are deleted from or functionally inactivated in the genome of an *E. coli W3110* host cell. While the *gtrA* and *gtrB* genes in different serotypes are highly homologous and interchangeable, the *gtrS* gene encodes a serotype-specific O-antigen glycosyl transferase. In *E. coli W3110* GtrS can transfer a glucose (Glc) residue to the GlcNAc sugar in the α -L-Rha-(1 \rightarrow 3)-D-G1cNAc motif of the *E. coli* O16 O-antigen.

As will be understood by the skilled person, the polypeptide of the invention comprised in a host cell of the invention, such as the carrier protein, oligosaccharyltransferase, the polypeptide having Wzy O-antigen polymerase activity and the other enzymes of the *rffB* gene cluster, are conveniently provided to the host cell in the form of nucleic acids encoding the polypeptides of the invention. The nucleic acids encoding the polypeptides of the invention preferably are nucleic acid constructs, specifically expression constructs comprising one or more expression cassettes for expression of the polypeptides of the invention, wherein nucleotide sequences encoding the polypeptides of the invention are operably linked to expression control sequences for expression of the polypeptides in the host cell of the invention. Suitable expression control sequences are referred to above and usually at least include a promoter. The promoter may be a constitutive promoter, or it may be a promoter of which the activity can be regulated, e.g. repressed or induced upon certain conditions, e.g. temperature changes or presence of certain chemicals or proteins in the cell, all of which are as such well known in the art. The nucleic acid constructs can be extrachromosomal, e.g. a plasmid or other vector, or nucleic acid constructs can be integrated into the genome of the host cell of the invention. Molecular biological methods for the construction and/or synthesis of the nucleic acid constructs for expression of the polypeptides in a host cell of the invention are generally well known in the art.

Optionally, the chain lengths of the O-antigens can be manipulated by manipulating the native Wzz O-antigen chain length regulator mechanism, e.g. by over-expression or supplementing a Wzz O-antigen chain regulator, e.g. by replacing an *E. coli wzzB* gene with one of its counterparts from species within *Salmonella* and *Shigella*, or from *P. aeruginosa*, e.g. a *Salmonella enterica* counterpart, *fepE* or other *wzz* homolog (see e.g., US 2018/0099038, WO 2020/039359), whereby for instance the number of repeat units of the O-antigen can be increased, with or without additional overexpression of the Wzy protein. The effects of *wzz*-like genes have been described in literature for these species. None of this is however needed to obtain bioconjugates with good immunogenicity, and in preferred embodiments bioconjugates according to the invention are prepared without manipulation of the Wzz chain length regulator mechanism.

In one embodiment, the yield of an *E. coli* O18 antigen bioconjugate produced with a host cell of the invention comprising a polypeptide having Wzy O-antigen polymerase activity and specific amino acids at indicated positions as defined herein above, is at least 105%, 110%, 120%,

150% or 200% of the yield produced when using the same conditions with an otherwise identical host cell that expresses the reference Wzy O-antigen polymerase having the amino acid sequence of SEQ ID NO: 1.

5 In one embodiment, the occupancy of glycosylation sites of a *E. coli* O18 antigen bioconjugate produced with a host cell of the invention comprising a polypeptide having Wzy O-antigen polymerase activity and specific amino acids at indicated positions as defined herein above, is improved over the occupancy of glycosylation sites of a bioconjugate produced when using the same conditions with an otherwise identical host cell that expresses the reference Wzy O-antigen polymerase having the amino acid sequence of SEQ ID NO: 1. Thus, in one embodiment, in a composition comprising an *E. coli* O18 antigen bioconjugate produced with a host cell of the invention and of which the carrier protein comprises 4 glycosylation sites, at least 50, 55, 60, 65, or 70% of the bioconjugate molecules are di-, tri- or tetra-glycosylated, i.e. have two to four of the glycosylation sites occupied. Preferably, in this embodiment, the carrier protein comprises an amino acid sequence with at least 80, 85, 90, 95, 96, 97, 98 or 99% sequence identity to SEQ ID NO: 3, comprising 4 glycosylation sites, comprising a glycosylation consensus sequence Asn-X-Ser(Thr), more preferably having SEQ ID NO: 4. Most preferably in this embodiment, the carrier protein comprises an EPA that comprises the amino acid sequence of SEQ ID NO: 3. In certain embodiments such compositions are periplasmic fraction of a host cell producing the O18 bioconjugate. Preferably such compositions comprise not more than 20%, 15%, 10%, of 15 20 bioconjugates with an average number of about 1-3 repeat units of O18 antigen ('sEPA').

In a further aspect, the invention further relates to methods wherein a host cell of the invention is used for producing a bioconjugate of an *E. coli* O18 antigen polysaccharide conjugated to a carrier protein. Thus, one embodiment pertains to a method for producing a bioconjugate of an *E. coli* O18 antigen polysaccharide conjugated to a carrier protein, wherein preferably, the method at least comprises the step of: a) culturing a host cell of the invention to produce the bioconjugate. In one embodiment, in step a) a host cell of the invention is cultured under conditions conducive to the production of the bioconjugate. In certain embodiments, the method relates to the production of an O18A bioconjugate. The host cell of the invention is cultured under conditions suitable for the expression of a bioconjugate that comprises a carrier protein covalently coupled to *E. coli* O18 antigen polysaccharide, such conditions are known to the person skilled in the art, using methods as for instance previously described in WO 2015/124769 or WO 2020/191082. 25 30

In one embodiment, the method for producing the O18 bioconjugate further comprises the step of: b) recovery of the bioconjugate. The O18 bioconjugate can be isolated, separated, and/or purified from recombinant host cells or culture medium using any method known in the art in view of the present disclosure. For example, the O18 bioconjugate can be purified by any method known in the art for purification of a protein, for instance, by chromatography (e.g., ion exchange, anionic exchange, affinity, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. See, e.g., Saraswat et al., 2013, Biomed. Res. Int., (p. 1-18); see also the methods described in WO 2009/104074. Further, the 35

bioconjugates can be fused to heterologous polypeptide sequences to facilitate purification. Methods to purify and characterize bioconjugates have been described in, e.g., Ihssen et al., 2010, supra, and in WO 2006/119987, WO 2009/104074, and in particular in WO 2015/124769 and WO 2017/035181, and WO2020/191082A1, the disclosures of each of these are incorporated by
5 reference herein.

In one embodiment, the method for producing the O18 bioconjugate further comprises the step of c): formulating the recovered bioconjugate into a pharmaceutical composition. Formulation of the bioconjugate into a pharmaceutical composition will usually involve preparing a composition comprising the bioconjugate of the invention and at least one pharmaceutically acceptable excipient
10 as herein described below in more detail. In one embodiment, the method for producing the O18 bioconjugate further comprises the addition of an adjuvant to the pharmaceutical composition comprising the bioconjugate. Suitable adjuvants for incorporation in a pharmaceutical composition are described herein below in more detail.

In one embodiment, the method for producing the O18 bioconjugate further comprises adding
15 one or more additional conjugates or bioconjugates of *E. coli* O-antigen polysaccharides conjugated to a carrier protein to the pharmaceutical composition to obtain a multivalent composition, preferably a multivalent bioconjugate composition. The one or more additional conjugates of *E. coli* O-antigen polysaccharides conjugated to a carrier protein are thus preferably bioconjugates of *E. coli* O-antigen polysaccharides of serotypes other than O18, or more preferably other than O18A. In a
20 preferred embodiment, the one or more additional conjugates or bioconjugates comprise at least one, two, three, four, five, six, seven, eight or all nine O-antigen polysaccharide selected from the group consisting of *E. coli* serotypes O1, O2, O4, O6, O8, O15, O16, O25 and O75. A detailed description of the *E. coli* O-antigen polysaccharide serotypes is provided herein below (see also Table 1). Such additional conjugates or bioconjugates can be obtained as described before, e.g. as
25 in WO2020/191082A1.

Thus, in one preferred embodiment, the method for producing the O18 bioconjugate further comprises adding additional bioconjugates of *E. coli* O-antigen polysaccharides conjugated to a carrier protein to the pharmaceutical composition to obtain a multivalent composition, wherein the multivalent bioconjugate composition comprises: (i) the bioconjugate of an *E. coli* O18A antigen
30 polysaccharide conjugated to a carrier protein; (ii) a bioconjugate of an *E. coli* O1A antigen polysaccharide conjugated to a carrier protein; (iii) a bioconjugate of an *E. coli* O2 antigen polysaccharide conjugated to a carrier protein; (iv) a bioconjugate of an *E. coli* glucosylated O4 antigen polysaccharide conjugated to a carrier protein; (v) a bioconjugate of an *E. coli* O6A antigen polysaccharide conjugated to a carrier protein; (vi) a bioconjugate of an *E. coli* O15 antigen
35 polysaccharide conjugated to a carrier protein; (vii) a bioconjugate of an *E. coli* O16 antigen polysaccharide conjugated to a carrier protein; (viii) a bioconjugate of an *E. coli* O25B antigen polysaccharide conjugated to a carrier protein; and
(ix) a bioconjugate of an *E. coli* O75 antigen polysaccharide conjugated to a carrier protein. In one embodiment, the multivalent bioconjugate composition further comprises: (x) a bioconjugate of an

E. coli O8 antigen polysaccharide conjugated to a carrier protein. Preferably, in these embodiments, the carrier protein in each bioconjugates (i) to (ix) comprises the amino acid sequence of SEQ ID NO: 3.

5 In another aspect, the invention pertains to use a host cell of the invention comprising a polypeptide having Wzy O-antigen polymerase activity and specific amino acids at indicated positions as defined herein above (i.e., having (i) I199, K377, and A395; or (ii) T199, K377, and V395; or (iii) T199, K377, and A395; or (iv) I199, K377, and V395; or (v) I199, M377, and A395; wherein in each case the positions are corresponding to positions of SEQ ID NO:1), for improving the occupancy of glycosylation sites of an *E. coli* O18 antigen bioconjugate. The improvement in the occupancy of glycosylation sites of an *E. coli* O18 antigen bioconjugate can for instance be observed by a decrease in the amount of bioconjugates with short repeat units (wherein n in the O18 structure of Table 1 is only about 1-3) and/or preferably by an increase in the amount of bioconjugates that consist of carrier proteins that comprise O18 antigen polysaccharides conjugated to at least two or more N-glycosylation consensus sequences in the carrier protein (and preferably wherein n in the O18 structure of Table 1 is at least 5), as compared to the occupancy of glycosylation sites of a bioconjugate produced when using the same conditions with an otherwise identical host cell that expresses the reference Wzy O-antigen polymerase having the amino acid sequence of SEQ ID NO: 1.

20 In another aspect, the invention pertains to a bioconjugate of an *E. coli* O18 antigen polysaccharide conjugated to a carrier protein that is obtained or obtainable in a method of the invention for producing the bioconjugate using a host cell of the invention as herein described above.

25 As used herein, the terms "conjugate", "glycoconjugate" and "bioconjugate" refer to a conjugation product containing an *E. coli* O-antigen covalently bound to a carrier protein. The conjugate of the invention preferably is a bioconjugate, which is a conjugation product produced in a host cell, wherein the O-antigen and the carrier protein are produced biosynthetically by the host cell's machinery, and wherein the O-antigen is also covalently attached to the carrier protein enzymatically, e.g., via N-linkages by the host cell's enzymes.

30 In yet another aspect, the invention pertains to a composition comprising a bioconjugate of an *E. coli* O18 antigen polysaccharide conjugated to a carrier protein that is obtained or obtainable in a method of the invention for producing the bioconjugate using a host cell of the invention as herein described above.

35 In one embodiment, a composition comprising a bioconjugate of an *E. coli* O18 antigen conjugated to a carrier protein, is a composition comprising a bioconjugate wherein the carrier protein comprises 4 glycosylation sites, and wherein at least 50, 55, 60, 65, or 70% of the carrier protein molecules in the composition is glycosylated with *E. coli* O18 antigen repeats at at least two of the N-glycosylation sequences, i.e. are di-, tri- or tetra-glycosylated and thus have two to four of the glycosylation sites occupied. Preferably, in this embodiment, the carrier protein comprises an amino acid sequence with at least 80, 85, 90, 95, 96, 97, 98 or 99% sequence identity to SEQ ID

NO: 3, comprising 4 glycosylation sites, comprising a glycosylation consensus sequence Asn-X-Ser(Thr), more preferably having SEQ ID NO: 4. Most preferably in this embodiment, the carrier protein comprises an EPA that comprises the amino acid sequence of SEQ ID NO: 3. In certain
5 bioconjugate. Preferably such compositions comprise not more than 20%, 15%, 10%, of bioconjugates with an average number of about 1-3 repeat units of *E. coli* O18 antigen polysaccharide ('sEPA').

In one embodiment, a composition comprising a bioconjugate of an *E. coli* O18 antigen conjugated to a carrier protein, is a pharmaceutical composition comprising, in addition to the
10 bioconjugate, a pharmaceutically acceptable excipient. The (pharmaceutical) compositions of the invention may comprise any pharmaceutically acceptable excipient including a carrier, filler, preservative, solubilizer and/or diluent. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable
15 excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. Further examples of suitable pharmaceutical carriers are well known to the skilled person and have been described in textbooks.

As used herein, the term "pharmaceutically acceptable carrier" refers to a non-toxic material that does not interfere with the effectiveness of a composition according to the invention or the
20 biological activity of a composition according to the invention. A "pharmaceutically acceptable carrier" can include any excipient, diluent, filler, salt, buffer, stabilizer, solubilizer, oil, lipid, lipid containing vesicle, microsphere, liposomal encapsulation, or other material well known in the art for use in pharmaceutical formulations. It will be understood that the characteristics of the pharmaceutically acceptable carrier will depend on the route of administration for a particular
25 application. According to particular embodiments, in view of the present disclosure, any pharmaceutically acceptable carrier suitable for use in a vaccine can be used in the invention. Suitable excipients include but are not limited to sterile water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof, as well as stabilizers, e.g. Human Serum Albumin (HSA) or other suitable proteins and reducing sugars.

30 Suitable buffers include Tris-buffered saline, phosphate buffer, and sucrose phosphate glutamate buffer. For example, a Tris-buffered saline (TBS) pH 7.4 (e.g. containing Tris, NaCl and KCl, e.g. at 25 mM, 137 mM and 2.7 mM, respectively); a phosphate buffer comprising about 10 mM $\text{KH}_2\text{PO}_4/\text{Na}_2\text{HPO}_4$ buffer at pH of about 7.0, about 5% (w/v) sorbitol, about 10 mM methionine, and about 0.02% (w/v) polysorbate 80; or a phosphate buffer comprising about 10 mM
35 $\text{KH}_2\text{PO}_4/\text{Na}_2\text{HPO}_4$ buffer at pH of about 7.0, about 8% (w/v) sucrose, about 1 mM EDTA, and about 0.02% (w/v) polysorbate 80.

Suitable salts include one or more of e.g., Tris-hydrochloride, sodium chloride, calcium chloride, potassium chloride, sodium phosphate, monosodium glutamate, and aluminum salts (e.g.,

aluminum hydroxide, aluminum phosphate, potassium aluminum sulfate, or a mixture of such aluminum salts).

Suitable preservatives include phenol, benzethonium chloride, 2-phenoxyethanol, or thimerosal at 0.001% to 0.01% (w/v) of the preservative. In other embodiments, no preservative is included.

The compositions may be formulated to be suitable for the intended route of administration to a subject. For example, the compositions can be formulated to be suitable for subcutaneous, parenteral, oral, intradermal, transdermal, colorectal, intraperitoneal, intravaginal, rectal, intravenous, buccal, intranasal, intratracheal, intramuscular, topical, transdermal, or pulmonary administration, preferably intramuscular administration.

The compositions of the invention can be included in a container, pack, or dispenser together with instructions for administration.

In certain embodiments, the compositions of the invention can be stored before use, e.g., the compositions can be stored frozen (e.g., at about -20°C or at about -70°C); stored in refrigerated conditions (e.g., at about 2-8°C, e.g. about 4°C); or stored at room temperature.

The pharmaceutical compositions optionally may comprise, or optionally may be administered in combination with, an adjuvant. The adjuvant for administration in combination with a composition of the invention can be administered before, concomitantly with, or after administration of the immunogenic compositions. In other preferred embodiments, the pharmaceutical compositions of the invention do not comprise an adjuvant, and/or are not administered in combination with an adjuvant.

As used herein, the term “adjuvant” refers to a compound that when administered in conjunction with or as part of a composition of the invention augments, enhances and/or boosts the immune response to a conjugate comprising *E. coli* O18-antigen coupled to a carrier protein, but when the adjuvant compound is administered alone does not generate an immune response to the conjugate. Adjuvants can enhance an immune response by several mechanisms including, e.g., lymphocyte recruitment, stimulation of B and/or T cells, and/or stimulation of antigen presenting cells.

Specific examples of adjuvants include, but are not limited to, aluminum salts (alum) (such as aluminum hydroxide, aluminum phosphate, aluminum sulfate, and aluminum oxide, including nanoparticles comprising alum or nanoalum formulations), calcium phosphate, monophosphoryl lipid A (MPL) or 3-de-O-acylated monophosphoryl lipid A (3D-MPL) (see e.g., United Kingdom Patent GB2220211, EP0971739, EP1194166, US6491919), AS01, AS02, AS03 and AS04 (all GlaxoSmithKline; see e.g. EP1126876, US7357936 for AS04, EP0671948, EP0761231, US5750110 for AS02), imidazopyridine compounds (see WO2007/109812), imidazoquinoxaline compounds (see WO2007/109813), delta-inulin, STING-activating synthetic cyclic-di-nucleotides (e.g. US20150056224), combinations of lecithin and carbomer homopolymers (e.g. US6676958), and saponins, such as Quil A and QS21, optionally in combination with QS7 (e.g. US 5,057,540). In some embodiments, the adjuvant is Freund's adjuvant (complete or incomplete). In certain

embodiments, the adjuvant comprises Quil-A, such as for instance commercially obtainable from Brenntag (now Croda) or Invivogen. QuilA contains the water-extractable fraction of saponins from the Quillaja saponaria Molina tree. These saponins belong to the group of triterpenoid saponins, that have a common triterpenoid backbone structure. Saponins are known to induce a strong
5 adjuvant response to T-dependent as well as T-independent antigens, as well as strong cytotoxic CD8+ lymphocyte responses and potentiating the response to mucosal antigens. They can also be combined with cholesterol and phospholipids, to form immunostimulatory complexes (ISCOMs), wherein QuilA adjuvant can activate both antibody-mediated and cell-mediated immune responses to a broad range of antigens from different origins. In certain embodiments, the adjuvant is AS01,
10 for example AS01B. AS01 is an adjuvant system containing MPL (3-O-desacyl-4'-monophosphoryl lipid A), QS21 (Quillaja saponaria Molina, fraction 21) and liposomes. In certain embodiments, the AS01 is commercially available (GSK) or can be made as described in WO 96/33739, incorporated herein by reference. Certain adjuvants comprise emulsions, which are mixtures of two immiscible fluids, e.g. oil and water, one of which is suspended as small drops inside the other, and are
15 stabilized by surface-active agents. Oil-in-water emulsions have water forming the continuous phase, surrounding small droplets of oil, while water-in-oil emulsions have oil forming the continuous phase. Certain emulsions comprise squalene (a metabolizable oil). Certain adjuvants comprise block copolymers, which are copolymers formed when two monomers cluster together and form blocks of repeating units. An example of a water in oil emulsion comprising a block
20 copolymer, squalene and a microparticulate stabilizer is TiterMax®, which can be commercially obtained from Sigma-Aldrich. Optionally emulsions can be combined with or comprise further immunostimulating components, such as a TLR4 agonist. Certain adjuvants are oil in water emulsions (such as squalene or peanut oil) also used in MF59 (see e.g. EP0399843, US 6299884, US6451325) and AS03, optionally in combination with immune stimulants, such as
25 monophosphoryl lipid A and/or QS21 such as in AS02 (see Stoute et al., 1997, N. Engl. J. Med. 336, 86-91). Further examples of adjuvants are liposomes containing immune stimulants such as MPL and QS21 such as in AS01E and AS01B (e.g. US 2011/0206758). Other examples of adjuvants are CpG, and imidazoquinolines (such as imiquimod and R848). See, e.g., Reed G, et al., 2013, Nature Med, 19: 1597-1608. In certain embodiments, the adjuvant is a Th1 adjuvant.

30 In certain embodiments, the adjuvant comprises saponins, preferably the water-extractable fraction of saponins obtained from Quillaja saponaria. In certain embodiments, the adjuvant comprises QS-21.

In certain embodiments, the adjuvant contains a toll-like receptor 4 (TLR4) agonist. TLR4 agonists are well known in the art, see e.g. Ireton GC and SG Reed, 2013, Expert Rev Vaccines
35 12: 793-807. In certain embodiments, the adjuvant is a TLR4 agonist comprising lipid A, or an analog or derivative thereof.

The adjuvant, for example including a TLR4 agonist, may be formulated in various ways, e.g. in emulsions such as water-in-oil (w/o) emulsions or oil-in-water (o/w) emulsions (examples are MF59, AS03), stable (nano-)emulsions (SE), lipid suspensions, liposomes, (polymeric)

nanoparticles, virosomes, alum adsorbed, aqueous formulations (AF), and the like, representing various delivery systems for immunomodulatory molecules in the adjuvant and/or for the immunogens.

5 The immunostimulatory TLR4 agonist may optionally be combined with other immunomodulatory components, such as saponins (e.g. QuilA, QS7, QS21, Matrix M, Iscoms, Iscomatrix, etc), aluminum salts, activators for other TLRs (e.g. imidazoquinolines, flagellin, dsRNA analogs, TLR9 agonists, such as CpG, etc), and the like (see e.g. Reed et al, 2013, supra).

10 As used herein, the term "lipid A" refers to the hydrophobic lipid moiety of an LPS molecule that comprises glucosamine and is linked to keto-deoxyoctulosonate in the inner core of the LPS molecule through a ketosidic bond, which anchors the LPS molecule in the outer leaflet of the outer membrane of Gram-negative bacteria. For an overview of the synthesis of LPS and lipid A structures, see, e.g., Raetz, 1993, J. Bacteriology 175:5745-5753, Raetz CR and C Whitfield, 2002, Annu Rev Biochem 71: 635-700; US 5,593,969 and US 5,191,072. Lipid A, as used herein includes naturally occurring lipid A, mixtures, analogs, derivatives and precursors thereof. The term includes
15 monosaccharides, e.g., the precursor of lipid A referred to as lipid X; disaccharide lipid A; hepta-acyl lipid A; hexa-acyl lipid A; penta-acyl lipid A; tetra-acyl lipid A, e.g., tetra-acyl precursor of lipid A, referred to as lipid IVA; dephosphorylated lipid A; monophosphoryl lipid A; diphosphoryl lipid A, such as lipid A from *Escherichia coli* and *Rhodobacter sphaeroides*. Several immune activating lipid A structures contain 6 acyl chains. Four primary acyl chains attached directly to the glucosamine
20 sugars are 3-hydroxy acyl chains usually between 10 and 16 carbons in length. Two additional acyl chains are often attached to the 3-hydroxy groups of the primary acyl chains. E. coli lipid A, as an example, typically has four C14 3-hydroxy acyl chains attached to the sugars and one C12 and one C14 attached to the 3-hydroxy groups of the primary acyl chains at the 2' and 3' position, respectively.

25 As used herein, the term "lipid A analog or derivative" refers to a molecule that resembles the structure and immunological activity of lipid A, but that does not necessarily naturally occur in nature. Lipid A analogs or derivatives may be modified to e.g. be shortened or condensed, and/or to have their glucosamine residues substituted with another amine sugar residue, e.g. galactosamine residues, to contain a 2-deoxy-2-aminogluconate in place of the glucosamine-1-
30 phosphate at the reducing end, to bear a galacturonic acid moiety instead of a phosphate at position 4'. Lipid A analogs or derivatives may be prepared from lipid A isolated from a bacterium, e.g., by chemical derivation, or chemically synthesized, e.g. by first determining the structure of the preferred lipid A and synthesizing analogs or derivatives thereof. Lipid A analogs or derivatives are also useful as TLR4 agonist adjuvants (see, e.g. Gregg KA et al, 2017, MBio 8, eDD492-17, doi:
35 10.1128/mBio.00492-17).

For example, a lipid A analog or derivative can be obtained by deacylation of a wild-type lipid A molecule, e.g., by alkali treatment. Lipid A analogs or derivatives can for instance be prepared from lipid A isolated from bacteria. Such molecules could also be chemically synthesized. Another example of lipid A analogs or derivatives are lipid A molecules isolated from bacterial cells harboring

mutations in, or deletions or insertions of enzymes involved in lipid A biosynthesis and/or lipid A modification.

MPL and 3D-MPL are lipid A analogs or derivatives that have been modified to attenuate lipid A toxicity. Lipid A, MPL and 3D-MPL have a sugar backbone onto which long fatty acid chains are attached, wherein the backbone contains two 6-carbon sugars in glycosidic linkage, and a phosphoryl moiety at the 4 position. Typically, five to eight long chain fatty acids (usually 12-14 carbon atoms) are attached to the sugar backbone. Due to derivation of natural sources, MPL or 3D-MPL may be present as a composite or mixture of a number of fatty acid substitution patterns, e.g. hepta-acyl, hexa-acyl, penta-acyl, etc., with varying fatty acid lengths. This is also true for some of the other lipid A analogs or derivatives described herein, however synthetic lipid A variants may also be defined and homogeneous. MPL and its manufacture are for instance described in US 4,436,727. 3D-MPL is for instance described in US 4,912,094B1, and differs from MPL by selective removal of the 3-hydroxymyristic acyl residue that is ester linked to the reducing-end glucosamine at position 3 (compare for instance the structure of MPL in column 1 vs 3D-MPL in column 6 of US 4,912,094B1). In the art often 3D-MPL is used, while sometimes referred to as MPL (e.g. the first structure in Table 1 of Ireton GC and SG Reed, 2013, supra, refers to this structure as MPL®, but actually depicts the structure of 3D-MPL).

Examples of lipid A (analogs, derivatives) include MPL, 3D-MPL, RC529 (e.g. EP1385541), PET-lipid A, GLA (glycopyranosyl lipid adjuvant, a synthetic disaccharide glycolipid; e.g. US20100310602, US8722064), SLA (e.g. Carter D et al, 2016, Clin Transl Immunology 5: e108 (doi: 10.1038/cti.2016.63), which describes a structure-function approach to optimize TLR4 ligands for human vaccines), PHAD (phosphorylated hexaacyl disaccharide; the structure of which is the same as that of GLA), 3D-PHAD, 3D-(6-acyl)-PHAD (3D(6A)-PHAD) (PHAD, 3D-PHAD, and 3D(6A)PHAD are synthetic lipid A variants, see e.g. avantilipids.com/divisions/adjuvants, which also provide structures of these molecules), E6020 (CAS Number 287180-63-6), ONO4007, OM-174, and the like. For exemplary chemical structures of 3D-MPL, RC529, PET-lipid A, GLA/PHAD, E6020, ONO4007, and OM-174, see e.g. Table 1 in Ireton GC and SG Reed, 2013, supra. For a structure of SLA, see e.g. Fig 1 in Reed SG et al, 2016, Curr Opin Immunol 41: 85-90. In certain preferred embodiments, the TLR4 agonist adjuvant comprises a lipid A analog or derivative chosen from 3D-MPL, GLA, or SLA. In certain embodiments the lipid A analog or derivative is formulated in liposomes.

Exemplary adjuvants comprising a lipid A analog or derivative include GLA-LSQ (synthetic MPL [GLA], QS21, lipids formulated as liposomes), SLA-LSQ (synthetic MPL [SLA], QS21, lipids, formulated as liposomes), GLA-SE (synthetic MPL [GLA], squalene oil/water emulsion), SLA-SE (synthetic MPL [SLA], squalene oil/water emulsion), SLA-Nanoalum (synthetic MPL [SLA], aluminum salt), GLA-Nanoalum (synthetic MPL [GLA], aluminum salt), SLA-AF (synthetic MPL [SLA], aqueous suspension), GLA-AF (synthetic MPL [GLA], aqueous suspension), SLA-alum (synthetic MPL [SLA], aluminum salt), GLA-alum (synthetic MPL [GLA], aluminum salt), and several of the GSK ASxx series of adjuvants, including AS01 (MPL, QS21, liposomes), AS02 (MPL, QS21,

oil/water emulsion), AS25 (MPL, oil/water emulsion), AS04 (MPL, aluminum salt), and AS15 (MPL, QS21, CpG, liposomes). See, e.g., WO 2013/119856, WO 2006/116423, US 4,987,237, U.S. 4,436,727, US 4,877,611, US 4,866,034, US 4,912,094, US 4,987,237, US5191072, US5593969, US 6,759,241, US 9,017,698, US 9,149,521, US 9,149,522, US 9,415,097, US 9,415,101, US
5 9,504,743, Reed G, et al., 2013, supra.

Non-glycolipid molecules may also be used as TLR4 agonist adjuvants, e.g. synthetic molecules such as Neoseptin-3 or natural molecules such as LelF, see e.g. Reed SG et al, 2016, supra.

In one embodiment, a composition of the invention comprising a bioconjugate of an *E. coli*
10 O18 antigen conjugated to a carrier protein, further comprises at least one additional conjugate comprising an *E. coli* O-antigen polysaccharide covalently coupled to a carrier protein. The one or more additional bioconjugates of *E. coli* O-antigen polysaccharides conjugated to a carrier protein preferably are bioconjugates of *E. coli* O-antigen polysaccharides of serotypes other than O18, or more preferably other than O18A. In a preferred embodiment, the one or more additional conjugates
15 or bioconjugates comprise at least one, two, three, four, five, six, seven, eight or all nine O-antigen polysaccharide selected from the group consisting of *E. coli* serotypes O1, O2, O4, O6, O8, O15, O16, O25 and O75.

In a preferred embodiment, the one or more additional *E. coli* O-antigens in the additional conjugate(s) are selected from the group consisting of *E. coli* O1 antigen polysaccharide (e.g. O1A antigen polysaccharide), *E. coli* O2 antigen polysaccharide, *E. coli* O4 antigen polysaccharide (e.g.
20 *E. coli* glucosylated O4 antigen polysaccharide), *E. coli* O6 antigen polysaccharide (e.g. O6A antigen polysaccharide), *E. coli* O8 antigen polysaccharide, *E. coli* O15 antigen polysaccharide, *E. coli* O16 antigen polysaccharide, *E. coli* O25 antigen polysaccharide (e.g. O25A or O25B antigen polysaccharide, preferably O25B antigen polysaccharide), and *E. coli* O75 antigen polysaccharide.
25 Preferably, each of the additional O-antigen polysaccharides is covalently linked to a carrier protein. In certain embodiments, each of the carrier proteins, *i.e.* the carrier protein for each conjugate, is an EPA carrier protein. Preferably, one or more, preferably all of the additional conjugates are bioconjugates.

As used herein, the term "O18" refers to the O18 antigen of *E. coli* (*E. coli* serotype O18),
30 and could be either O18A, O18B, O18A1, or O18B1 antigen (each of the four subserotypes of *E. coli* serotype O18), and in preferred embodiments O18 refers to O18A. The O18A antigen polysaccharide may comprise the structure of formula (O18A) as shown in Table 1, wherein n is an integer of 1-100, e.g. 3-50, preferably 5-40, e.g. 7 to 25, e.g. 10 to 20. The term "O1A" refers to the O1A antigen of *E. coli* (a subserotype of *E. coli* serotype O1). The term "O2" refers to the O2 antigen
35 of *E. coli* (*E. coli* serotype O2). The term "O4" refers to the O4 antigen of *E. coli* (*E. coli* serotype O4), which may or may not include a glucose side-branch (referred to as Glucosylated O4 antigen polysaccharide (O4-Glc+), and Non-glucosylated O4 antigen polysaccharide (O4-Glc-), respectively; in preferred embodiments O4 is O4-Glc+). The term "O6A" refers to the O6A antigen of *E. coli* (a subserotype of *E. coli* serotype O6). The term "O8" refers to the O8 antigen of *E. coli*

(*E. coli* serotype O8). The term “O15” refers to the O15 antigen of *E. coli* (*E. coli* serotype O15). The term “O16” refers to the O16 antigen of *E. coli* (*E. coli* serotype O16). The term “O25B” refers to the O25B antigen from *E. coli* (a subserotype of *E. coli* serotype O25). The term “O75” refers to the O75 antigen of *E. coli* (*E. coli* serotype O75).

- 5 The structures of *E. coli* O-antigen polysaccharides referred to throughout this application are shown below in Table 1. A single repeating unit for each *E. coli* O-antigen polysaccharide is shown.

Table 1: Structures of *E. coli* O-antigen Polysaccharides

<i>E. coli</i> O-antigen Polysaccharide	Structure of Repeating Unit ¹
Non-glucosylated O4 antigen polysaccharide (O4-Glc-)	$[\rightarrow 2)\text{-}\alpha\text{-L-Rhap}\text{-}(1\rightarrow 6)\text{-}\alpha\text{-D-Glcp}\text{-}(1\rightarrow 3)\text{-}\alpha\text{-L-FucpNAc}\text{-}(1\rightarrow 3)\text{-}\beta\text{-D-GlcpNAc}\text{-}(1\rightarrow)]_n$
Glucosylated O4 antigen polysaccharide (O4-Glc+)	$\begin{array}{c} \alpha\text{-D-Glcp} \\ \\ 1 \\ \vdots \\ 3 \\ \\ [\rightarrow 2)\text{-}\alpha\text{-L-Rhap}\text{-}(1\rightarrow 6)\text{-}\alpha\text{-D-Glcp}\text{-}(1\rightarrow 3)\text{-}\alpha\text{-L-FucpNAc}\text{-}(1\rightarrow 3)\text{-}\beta\text{-D-GlcpNAc}\text{-}(1\rightarrow)]_n \end{array}$
O1A antigen polysaccharide (O1A)	$\begin{array}{c} [\rightarrow 3)\text{-}\alpha\text{-L-Rhap}\text{-}(1\rightarrow 3)\text{-}\alpha\text{-L-Rhap}\text{-}(1\rightarrow 3)\text{-}\beta\text{-L-Rhap}\text{-}(1\rightarrow 4)\text{-}\beta\text{-D-GlcpNAc}\text{-}(1\rightarrow)]_n \\ \\ 2 \\ \\ 1 \\ \\ \beta\text{-D-ManpNAc} \end{array}$
O2 antigen polysaccharide (O2)	$\begin{array}{c} [\rightarrow 3)\text{-}\alpha\text{-L-Rhap}\text{-}(1\rightarrow 2)\text{-}\alpha\text{-L-Rhap}\text{-}(1\rightarrow 3)\text{-}\beta\text{-L-Rhap}\text{-}(1\rightarrow 4)\text{-}\beta\text{-D-GlcpNAc}\text{-}(1\rightarrow)]_n \\ \\ 2 \\ \\ 1 \\ \\ \alpha\text{-D-Fucp3NAc} \end{array}$

O6A antigen polysaccharide (O6A)	$\begin{array}{c} [\rightarrow 4)\text{-}\alpha\text{-D-GalpNAc}\text{-}(1\rightarrow 3)\text{-}\beta\text{-D-Manp}\text{-}(1\rightarrow 4)\text{-}\beta\text{-D-Manp}\text{-}(1\rightarrow 3)\text{-}\alpha\text{-D-GlcpNAc}\text{-}(1\rightarrow)]_n \\ \\ 2 \\ \\ 1 \\ \\ \beta\text{-D-Glcp} \end{array}$
O8 antigen polysaccharide (O8)	$[\rightarrow 3)\text{-}\beta\text{-D-Manp3Me}\text{-}(1\rightarrow 3)\text{-}\beta\text{-D-Manp}\text{-}(1\rightarrow 2)\text{-}\alpha\text{-D-Manp}\text{-}(1\rightarrow 2)\text{-}\alpha\text{-D-Manp}\text{-}(1\rightarrow)]_n$
O15 antigen polysaccharide (O15)	$[\rightarrow 2)\text{-}\beta\text{-D-Galp}\text{-}(1\rightarrow 3)\text{-}\alpha\text{-L-FucpNAc}\text{-}(1\rightarrow 3)\text{-}\beta\text{-D-GlcpNAc}\text{-}(1\rightarrow)]_n$
O16 antigen polysaccharide (O16)	$\begin{array}{c} [\rightarrow 2)\text{-}\beta\text{-D-Galf}\text{-}(1\rightarrow 6)\text{-}\alpha\text{-D-Glcp}\text{-}(1\rightarrow 3)\text{-}\alpha\text{-L-Rhap}\text{-}(1\rightarrow 3)\text{-}\alpha\text{-D-GlcpNAc}\text{-}(1\rightarrow)]_n \\ \\ 2 \\ \\ \text{Ac} \end{array}$
O18A antigen polysaccharide (O18A)	$\begin{array}{c} [\rightarrow 2)\text{-}\alpha\text{-L-Rhap}\text{-}(1\rightarrow 6)\text{-}\alpha\text{-D-Glcp}\text{-}(1\rightarrow 4)\text{-}\alpha\text{-D-Galp}\text{-}(1\rightarrow 3)\text{-}\alpha\text{-D-GlcpNAc}\text{-}(1\rightarrow)]_n \\ \\ 3 \\ \\ 1 \\ \\ \beta\text{-D-GlcpNAc} \end{array}$
O18B antigen polysaccharide (O18B)	$\begin{array}{c} [\rightarrow 3)\text{-}\alpha\text{-L-Rhap}\text{-}(1\rightarrow 6)\text{-}\alpha\text{-D-Glcp}\text{-}(1\rightarrow 4)\text{-}\alpha\text{-D-Galp}\text{-}(1\rightarrow 3)\text{-}\alpha\text{-D-GlcpNAc}\text{-}(1\rightarrow)]_n \\ \\ 3 \\ \\ 1 \\ \\ \beta\text{-D-Glcp} \end{array}$

<p>O18A1 antigen polysaccharide (O18A1)</p>	$ \begin{array}{c} \alpha\text{-D-Glcp} \\ \downarrow \\ 1 \\ \downarrow \\ 6 \\ [\rightarrow 2)\text{-}\alpha\text{-L-Rhap}\text{-}(1\rightarrow 6)\text{-}\alpha\text{-D-Glcp}\text{-}(1\rightarrow 4)\text{-}\alpha\text{-D-Galp}\text{-}(1\rightarrow 3)\text{-}\alpha\text{-D-GlcpNAc}\text{-}(1\rightarrow]_n \\ \uparrow \\ 3 \\ \uparrow \\ 1 \\ \beta\text{-D-GlcpNAc} \end{array} $
<p>O18B1 antigen polysaccharide (O18B1)</p>	$ \begin{array}{c} \alpha\text{-D-Glcp} \\ \downarrow \\ 1 \\ \downarrow \\ 4 \\ [\rightarrow 3)\text{-}\alpha\text{-L-Rhap}\text{-}(1\rightarrow 6)\text{-}\alpha\text{-D-Glcp}\text{-}(1\rightarrow 4)\text{-}\alpha\text{-D-Galp}\text{-}(1\rightarrow 3)\text{-}\alpha\text{-D-GlcpNAc}\text{-}(1\rightarrow]_n \\ \uparrow \\ 3 \\ \uparrow \\ 1 \\ \beta\text{-D-Glcp} \end{array} $
<p>O25B antigen polysaccharide (O25B)</p>	$ \begin{array}{c} \beta\text{-D-Glcp} \\ \downarrow \\ 1 \\ \downarrow \\ 6 \\ [\rightarrow 4)\text{-}\alpha\text{-D-Glcp}\text{-}(1\rightarrow 3)\text{-}\alpha\text{-L-Rhap}\text{-}(1\rightarrow 3)\text{-}\beta\text{-D-GlcpNAc}\text{-}(1\rightarrow]_n \\ \uparrow \qquad \qquad \uparrow \\ 3 \qquad \qquad \qquad 2 \\ \uparrow \qquad \qquad \qquad \uparrow \\ 1 \qquad \qquad \qquad \text{Ac} \\ \alpha\text{-L-Rhap} \end{array} $
<p>O75 antigen polysaccharide (O75)</p>	$ \begin{array}{c} \beta\text{-D-Manp} \\ \downarrow \\ 1 \\ \downarrow \\ 4 \\ [\rightarrow 3)\text{-}\alpha\text{-D-Galp}\text{-}(1\rightarrow 4)\text{-}\alpha\text{-L-Rhap}\text{-}(1\rightarrow 3)\text{-}\beta\text{-D-GlcpNAc}\text{-}(1\rightarrow]_n \end{array} $

¹ Each n is independently an integer of 1 to 100, such as 1-50, 1-40, 1-30, 1-20, and 1-10, 3-50, 5-3-40, e.g. at least 5, such as 5-40, e.g. 7-30, e.g. 7 to 25, e.g. 10 to 20

All monosaccharides described herein have their common meaning known in the art. Monosaccharides can have the D or L configuration. If D or L is not specified, the sugar is understood to have the D configuration. Monosaccharides are typically referred to by abbreviations commonly known and used in the art. For example, Glc refers to glucose; D-Glc refers to D-glucose; and L-Glc refers to L-glucose. Other common abbreviations for monosaccharides include: Rha, rhamnose; GlcNAc, N-acetylglucosamine; GalNAc, N-acetylgalactosamine; Fuc, fucose; Man, mannose; Man3Me, 3-O-methyl-mannose; Gal, galactose; FucNAc, N-acetylfucosamine; and Rib, ribose. The suffix "f" refers to furanose and the suffix "p" refers to pyranose.

A composition comprising the bioconjugate of a carrier protein covalently coupled to *E. coli* O18 antigen polysaccharide according to the invention, may further comprise at least one additional conjugate of a carrier protein covalently coupled to an *E. coli* O-antigen polysaccharide, and in certain embodiments the at least one additional conjugate comprises an *E. coli* O-antigen polysaccharide that is selected from the group consisting of *E. coli* O1A antigen polysaccharide, *E. coli* O2 antigen polysaccharide, *E. coli* O4 antigen polysaccharide, *E. coli* O6A antigen polysaccharide, *E. coli* O8 antigen polysaccharide, *E. coli* O15 antigen polysaccharide, *E. coli* O16 antigen polysaccharide, *E. coli* O25B antigen polysaccharide, and *E. coli* O75 antigen polysaccharide. Such compositions can be prepared by adding together the conjugates to obtain a multivalent conjugate composition. Preferably one or more and preferably all of the additional conjugates are also bioconjugates.

In certain embodiments, an O1A antigen polysaccharide (e.g., in isolated form or as part of a glycoconjugate, preferably a bioconjugate) is present in a (pharmaceutical) composition as provided herein (e.g., a composition comprising the *E. coli* O18 bioconjugate obtained by the method as described herein). The O1A antigen polysaccharide may comprise the structure of formula (O1A) as shown in Table 1, wherein n is an integer of 1-100, e.g. 3-50, preferably 5-40, e.g. 7 to 25, e.g. 10 to 20. Preferably, the O1A antigen polysaccharide is part of a conjugate, more preferably of a bioconjugate, and is covalently linked to a carrier protein, e.g., EPA.

In certain embodiments, an O2 antigen polysaccharide (e.g., in isolated form or as part of a glycoconjugate, preferably a bioconjugate) is present in a (pharmaceutical) composition as provided herein (e.g., a composition comprising the *E. coli* O18 bioconjugate obtained by the method as described herein). The O2 antigen polysaccharide may comprise the structure of formula (O2) as shown in Table 1, wherein n is an integer of 1-100, e.g. 3-50, preferably 5-40, e.g. 7 to 25, e.g. 10 to 20. Preferably, the O2 antigen polysaccharide is part of a conjugate, more preferably of a bioconjugate, and is covalently linked to a carrier protein, e.g., EPA.

In certain embodiments, an O4 antigen polysaccharide (e.g., in isolated form or as part of a glycoconjugate, preferably a bioconjugate) is present in a (pharmaceutical) composition as provided herein (e.g., a composition comprising the *E. coli* O18 bioconjugate obtained by the method as described herein). O-antigen structural modification is known to exist within the *E. coli* O4 serotype. In particular, some O4 serotypes express a modified O-antigen having a branched glucose unit. As used herein, "glucosylated O4 antigen", "glucosylated O4 antigen polysaccharide", "glucose-

branched O4", "O4-Glc+ antigen polysaccharide", "Glc+ O4", and "O4-Glc+ antigen" refer to an O4 antigen having a glucose branch. Some O4 serotypes have an O4 antigen without such a branched glucose unit, and this is referred to herein as "non-glucosylated O4 antigen", "non-glucosylated O4 antigen polysaccharide", "O4-Glc- antigen", or "O4-Glc-". When referring to "O4 antigen" herein, this may be either O4-Glc+ antigen or O4-Glc- antigen. In preferred embodiments O4 refers to O4-Glc+ antigen. Structures of *E. coli* non-glucosylated O4 antigen and *E. coli* glucosylated O4 antigen are shown in formulas (O4-Glc-) and (O4-Glc+), respectively, in Table 1, wherein n is an integer of 1 to 100, e.g. 3 to 50, preferably 5 to 40, e.g. 7 to 25, e.g. 10 to 20. Methods to specifically produce O4-Glc+ bioconjugates have been described in WO2020/191082A1 which is herein incorporated in its entirety. Preferably, the O4 antigen polysaccharide is part of a conjugate, more preferably of a bioconjugate, and is covalently linked to a carrier protein, e.g., EPA.

In certain embodiments, an O6A antigen polysaccharide (e.g., in isolated form or as part of a glycoconjugate, preferably a bioconjugate) is present in a (pharmaceutical) composition as provided herein (e.g., a composition comprising the *E. coli* O18 bioconjugate obtained by the method as described herein). The O6A antigen polysaccharide may comprise the structure of formula (O6A) as shown in Table 1, wherein n is an integer of 1-100, e.g. 3-50, preferably 5-40, e.g. 7 to 25, e.g. 10 to 20. Preferably, the O6A antigen polysaccharide is part of a conjugate, more preferably of a bioconjugate, and is covalently linked to a carrier protein, e.g., EPA.

In certain embodiments, an O8 antigen polysaccharide (e.g., in isolated form or as part of a glycoconjugate, preferably a bioconjugate) is present in a (pharmaceutical) composition as provided herein (e.g., a composition comprising the *E. coli* O18 bioconjugate obtained by the method as described herein). The O8 antigen polysaccharide may comprise the structure of formula (O8) as shown in Table 1, wherein n is an integer of 1-100, e.g. 3-50, preferably 5-40, e.g. 7 to 25, e.g. 10 to 20. Preferably, the O8 antigen polysaccharide is part of a conjugate, more preferably of a bioconjugate, and is covalently linked to a carrier protein, e.g., EPA.

In certain embodiments, an O15 antigen polysaccharide (e.g., in isolated form or as part of a glycoconjugate, preferably a bioconjugate) is present in a (pharmaceutical) composition as provided herein (e.g., a composition comprising the *E. coli* O18 bioconjugate obtained by the method as described herein). The O15 antigen polysaccharide may comprise the structure of formula (O15) as shown in Table 1, wherein n is an integer of 1-100, e.g. 3-50, preferably 5-40, e.g. 7 to 25, e.g. 10 to 20. Preferably, the O15 antigen polysaccharide is part of a conjugate, more preferably of a bioconjugate, and is covalently linked to a carrier protein, e.g., EPA.

In certain embodiments, an O16 antigen polysaccharide (e.g., in isolated form or as part of a glycoconjugate, preferably a bioconjugate) is present in a (pharmaceutical) composition as provided herein (e.g., a composition comprising the *E. coli* O18 bioconjugate obtained by the method as described herein). The O16 antigen polysaccharide may comprise the structure of formula (O16) as shown in Table 1, wherein n is an integer of 1-100, e.g. 3-50, preferably 5-40, e.g. 7 to 25, e.g. 10 to 20. Preferably, the O16 antigen polysaccharide is part of a conjugate, more preferably of a bioconjugate, and is covalently linked to a carrier protein, e.g., EPA. A conjugate of an *E. coli* O16

antigen polysaccharide covalently linked to a carrier protein may have a certain degree of acetylation at position 2 of the L-Rha sugar. The degree of this O-acetylation of O16 antigen polysaccharide in a conjugate is preferably at least 30%, preferably at least 50%, such as at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%.

5 In certain embodiments, an O25B antigen polysaccharide (e.g., in isolated form or as part of a glycoconjugate, preferably a bioconjugate) is present in a (pharmaceutical) composition as provided herein (e.g., a composition comprising the *E. coli* O18 bioconjugate obtained by the method as described herein). The O25B antigen polysaccharide may comprise the structure of formula (O25B) as shown in Table 1, wherein n is an integer of 1-100, e.g. 3-50, preferably 5-40,
10 e.g. 7 to 25, e.g. 10 to 20. Preferably, the O25B antigen polysaccharide is part of a conjugate, more preferably of a bioconjugate, and is covalently linked to a carrier protein, e.g., EPA. Similarly to the O16 antigen polysaccharide as described above, a conjugate of an *E. coli* O25B antigen polysaccharide covalently linked to a carrier protein may have a certain degree of acetylation at position 2 of the L-Rha sugar. The degree of this O-acetylation of an *E. coli* O25B antigen
15 polysaccharide in a conjugate is preferably at least 30%, preferably at least 50%, such as at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%.

In certain embodiments, an O75 antigen polysaccharide (e.g., in isolated form or as part of a glycoconjugate, preferably a bioconjugate) is present in a (pharmaceutical) composition as provided herein (e.g., a composition comprising the *E. coli* O18 bioconjugate obtained by the method as
20 described herein). The O75 antigen polysaccharide may comprise the structure of formula (O75) as shown in Table 1, wherein n is an integer of 1-100, e.g. 3-50, preferably 5-40, e.g. 7 to 25, e.g. 10 to 20. Preferably, the O75 antigen polysaccharide is part of a conjugate, more preferably of a bioconjugate, and is covalently linked to a carrier protein, e.g., EPA.

In certain embodiments, a composition according to the invention comprises the bioconjugate
25 comprising carrier protein covalently coupled to *E. coli* O18 antigen polysaccharide according to the invention, and further comprises one or more additional conjugates comprising a carrier protein covalently coupled to an *E. coli* O-antigen polysaccharide, preferably 4 to 25 of such additional conjugates. Preferably the additional conjugates comprise one or more of the *E. coli* O-antigen polysaccharides as described above, most preferably at least O25B, O1A, O2, and O6. Particularly
30 preferred are compositions that comprise at least 7, preferably at least 8 additional conjugates, and preferably some and most preferably all of these additional conjugates are bioconjugates.

In preferred embodiments, a composition according to the invention comprises at least the *E. coli* O1A, O2, O4 (preferably glucosylated O4), O6A, O15, O16, O18 (preferably O18A), O25B and O75 antigen polysaccharides, preferably conjugates of the O1A, O2, glucosylated O4, O6A,
35 O15, O16, O18A, O25B and O75 antigen polysaccharides each independently covalently linked to a carrier protein, e.g., EPA (i.e., an at least 9-valent composition). In certain embodiments, such compositions comprise further an *E. coli* O8 antigen polysaccharide, preferably in the form of a conjugate, preferably a bioconjugate. In certain embodiments, such compositions (with or without O8 antigen polysaccharide) comprise additional *E. coli* O-antigen polysaccharides from other

serotypes, preferably conjugated to carrier protein, preferably bioconjugates, e.g. from 2-10 additional serotypes. In certain embodiments, pharmaceutical compositions are provided that comprise at least nine bioconjugates, wherein each bioconjugate comprises a carrier protein covalently linked to an *E. coli* O-antigen polysaccharide from different serotype, wherein the
5 serotypes include O18A (and the O18A bioconjugate is a bioconjugate according to the present invention, that was prepared using a method according to the present invention), O1A, O2, O4-Glc+, O6A, O15, O16, O25B, and O75. In certain embodiments the carrier protein is EPA, e.g. EPA having the amino acid sequence of SEQ ID NO: 3.

Compositions according to the invention may optionally comprise or be combined with or
10 administered together with further proteins, carbohydrates and lipo-saccharides to which an immune response is desired.

In another aspect, the invention relates to a pharmaceutical composition of the invention for use as a medicament.

In a further aspect, the invention relates to the use of a pharmaceutical composition as
15 described herein as a medicament for inducing an immune response against *E. coli*.

As used herein the terms "immunogen" or "immunogenic" or "antigen" are used interchangeably to describe a molecule to which an immunological response can be generated upon administration to a recipient, either alone, in conjunction with an adjuvant, or presented on a display vehicle.

20 As used herein, an "immunological response" or "immune response" to an antigen or composition refers to the development in a subject of a humoral and/or a cellular immune response to the antigen or an antigen present in the composition.

In certain embodiments, the pharmaceutical composition as described herein is for use in the prevention or treatment of a disease caused by an *E. coli* infection. In preferred embodiment, the
25 disease caused by an *E. coli* infection is invasive extra-intestinal pathogenic *E. coli* (ExPEC) disease (IED).

As used herein, the term "extra-intestinal pathogenic *E. coli*" or "ExPEC" refers to genetically related pathogenic *E. coli* strains that commonly invade, colonize, and induce disease in bodily sites outside of the gastrointestinal tract. ExPEC bacteria include uropathogenic (UPEC) *E. coli*, newborn meningitic (NMEC) *E. coli*, septicaemia associated (SePEC) *E. coli*, adherent invasive (AIEC) *E. coli*, and avian pathogenic (APEC) *E. coli*. Diseases associated with ExPEC or ExPEC infections include, but are not limited to, urinary tract infection (UTI), surgical-site infection, bacteremia, abdominal or pelvic infection, such as intra-abdominal infections (IAI), pneumonia, nosocomial pneumonia, osteomyelitis, cellulitis, pyelonephritis, wound infection, meningitis, neonatal
35 meningitis, peritonitis, cholangitis, soft-tissue infections, pyomyositis, septic arthritis, and sepsis.

In a further aspect, the invention pertains to a method of preventing or treating a disease caused by an *E. coli* infection, in particular an invasive extra-intestinal pathogenic *E. coli* (ExPEC) disease (IED) in a subject in need therefore, the method comprising the administration of an effective amount of the pharmaceutical composition as described herein.

As used herein, the term "effective amount" refers to an amount of an active ingredient or component that elicits the desired biological or medicinal response in a subject. An effective amount can be determined empirically and in a routine manner, in relation to the stated purpose. For example, in vitro assays can optionally be employed to help identify optimal dosage ranges.

5 As used herein, "subject" or "patient" means any animal, preferably a mammal, most preferably a human, who will be or has been vaccinated by a method or composition according to an embodiment of the invention. The term "mammal" as used herein, encompasses any mammal. Examples of mammals include, but are not limited to, cows, horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guinea pigs, monkeys, humans, etc., most preferably a human. In certain
10 embodiments, a subject is a human adult. As used herein, the term "human adult" refers to a human that is 18 years or older. In certain embodiments, the subject is one or more of: (i) a human female between about 16 and about 50 years old, e.g. between about 16 and about 35 years old;

(ii) a human adult more than 50 years old, or more than 55 years old, or more than 60 years old, or more than 65 years old;

15 (iii) a human subject suffering from reoccurring UTIs;

(iv) a human subject having or at risk of acquiring *E. coli* bacteremia or sepsis;

(v) a human subject that has a condition which requires catheter usage;

(vi) a human subject that undergoes a pre-scheduled surgery;

(vii) a human post-menopausal woman; or

20 (viii) a human subject that has diabetes.

In yet a further aspect, the invention also relates to the use of the pharmaceutical composition as described herein for the manufacture of a vaccine or a medicament for preventing or treating a disease caused by an *E. coli* infection, in particular an invasive extra-intestinal pathogenic *E. coli* (ExPEC) disease (IED).

25 Various publications, articles and patents are cited or described in the background and throughout the specification; each of these references is herein incorporated by reference in its entirety. Discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is for the purpose of providing context for the invention. Such discussion is not an admission that any or all of these matters form part of the prior art with respect
30 to any inventions disclosed or claimed.

DESCRIPTION OF THE SEQUENCES

Table 2: Sequences

Description	SEQUENCE	SEQ ID NO.
Wzy O18 polymerase (amino acid sequence)	MIYILTLTLLLVIAMFSLGTKSRITSPLPLHFLPWLLTLIVGISNYDQFYEFNER SFYSLLIWFTVIFIFYFYGELVNYKRENINVYYGLSHIKYECKKYWIIVIPISLYTI FEIYMVGMGGADGFFLNRLANTLEGYTGKKFILMPAVYPLMMAMFAIVCLTKTSKL NKYSIYFWMFLYCI GTMGKFSILTPILTYLI IYDFKHRLKVKKT IKFTLLII I LALT LHFTMAENDHSTFLSILGLYIYSPI IALGQLNEVNSSHFGEYTFRFIYAITNKIGL IKELPVNTILDYSYVPVPTNVYTALQPFYQDFGYTGII FGAVLYGLIYVSLYTAGVR GNNTQALLIYALFSVSSATAFFAETLVNLAGNVMVLVCTILLWRFTVICKPVQ	1
Wzy O18 polymerase (nucleic acid sequence)	ATGATATATATATTAACCTTTAACTCTTCTTAGTTATAGCCATAATGTTTTCTCTT CTGGCACAAAAAGTAGGATCACATCTCCATTACCTTTGCATTTTTTACCATGGTTA CTAACCTTTAATTGTCTGGGATAAGTAATTACGATCAATTTTACGAGTTAATGAAAGA AGCTTTTACTCTTTGTTGATTTGGTTTACAGTTATTTTTATATTTTATTTTCATAGGG GAACCTGGTTAATTATAAACGTGAAAATATAAATGTTTATTATGGTCTTTCACATATT AAATATGAATGTAAAAAATATTGGATCATTGTCATCCAATTTTATTATATACCATT TTCGAAATATATATGGTTGGTATGGGGGAGCAGATGGATTCTTCTCAATTTACGT CTTGCAAATACATTGGAGGGCTATACGGGTAAAAAATTTATCTTAATGCCTGCTGTA TATCCTCTAATGATGGCTATGTTTCGCAATTTGTTGTCTAACAAAACTTCCAAATTA AATAAATACTCCATTTATTTCTGGATGTTTTTGTATTGTATTGGCACAAATGGGAAAA TTTTCAATATTAACGCCAATATTGACATATTTAATTATTTATGACTTCAAACATAGA TTAAGTAAAAAACAATAAAGTTTACATTGTTGATAATTATATTAGCTTTAACT TTGCATTTTACACGTATGGCTGAGAATGACCACTCAACATTTTATCTATTTTAGGG CTCTATATTTATTACCAATAATTGCTTTAGGCCAGTTGAATGAAGTAAATAGTAGT CATTTTGGTGAGTATACGTTTAGATTTCATATATGCTATAACTAATAAAATTTGGCCTT ATTAAGAATTGCCAGTAAATACTATTCTTGACTATTTCATACGTTCTGTACCAACA AATGTATATACTGCACCTCAACCATTTTACCAGGATTTTGGTTATACTGGCATCATA TTTGGAGCAGTATTATACGGACTAATATATGTGAGTTTATACACGGCCGGTGTTCGT GGAAATAATACACAGGCATTACTGATTTACGCATTGTTTTTCTAGTTAGCAGTCAACG GCTTTCTTCGCTGAAACGCTAGTAACGAATTTAGCTGGAAATGTGATGTTAGTATTA TGTACCATCTTACTATGGCGATTTACAGTAATATGCAAACCAGTACAGTAA	2
Detoxified EPA protein comprising 4 optimized N-glycosylation sequences	GSGGGDQDATGSGGGKLAEEAFDLWNECAKACVLDLKDGVRSRMSVDPADTNGQ GVLHYSMVLEGGNDALKLAIDNALSITSDGLTIRLEGGVEPNKPVRYSYTRQARGSW SLNWLVP I GHEKPSNIKVFIHELNAGNQLSHMSP I YTIEMGDELLAKLARDATFFVR AHESNEMQPTLAI SHAGVSVVMAQAQPRREKRWSEWASGKVLCLLDPDGVNYLAQ QRCNLDDTWEGKIYRVLAGNPAKHDLDIKDNMNSTPTVISHRLHFPEGGSLAALTAH QACHLPLEAFTRHRQPRGWEQLEQCQGPVQRLVALYLAARLSWNQVDQVIRNALASP GSGGDLGEAIREQPEQARLALTLAAAESERFVRQGTGNDEAGAASADVSLTCEPVAK DQNRKTEGECAGPADSGDALLERNYPTGAEFLGDGGDVSFSTRGTQNWTVRLLQHR QLEERGYVFGYHGTFLAAQSIVFGGVRARSQDLDAIWRGFYIAGDPALAYGYAQD QEPDARGRIRNGALLRVYVPRWSLPGFYRTGLTLAAPEAAAGEVERLIGHPLPLRLDA ITGPEEEGGRVTILGWPLAERTVVI PSAIPTDPRNVGGDLDPSSI PDKEQAI SALPD YASQPGKPPREDLKLGGGGDQDAT	3
Optimized N-glycosylation consensus sequence	Asp(Glu)-X-Asn-Z-Ser(Thr), wherein X and Z are independently selected from any natural amino acid except Pro	4

Description	SEQUENCE	SEQ ID NO.
the <i>rfb</i> gene cluster of O18A	ATGACGAATTTAAAAGCAGTTATTCTGTAGCGGGTCTTGGGATGCATATGTTGCCT GCCACTAAGGCGATTCCCAAAGAGATGCTACCGATCGTCGACAAGCCAATGATTCAG TACATCGTTGACGAGATTGTGGCTGCAGGGATCAAAGAAAATCCTCCTGGTAACTCAC GCGTCCAAGAACGCGGTGCGAAAACCACTTCGACACCTCTTATGAATTAGAATCTCTC CTTGAACAGCGCGTGAAGCGTCAACTGCTGGCGGAAGTACAGTCCATTTGCCCGCCG GCGGTGACAATTATGAACGTGCGTCAGGGCGAACCTTTAGGTTTGGGCCACTCCATT TTATGTGCACGACCTGCCATTGGTGACAATCCATTTGTCGTGGTGTGCCAGACGTT GTGATCGACGACGCCAGCGCCGACCCGCTGCGCTACAACCTTGTGCCATGATTGCCG CGCTTTAACGAAAATGGCCGACGCCAGGTTCTGGCAAAACGCATGCCGGGCGATCTC TCTGAATACTCCGTCATCCAGACTAAAGAACCCTTGATCGCGAAGGTAAGTCAGC CGCATTGTTGAATTTATCGAAAACCGGATCAGCCGACAGCCCTGGACTCAGACATC ATGGCTGTAGGGCGTTATGTGCTTTCTGCCGATATTTGGCTGAACTGGAGCGTACT CAACCTGGAGCATGGGGACGTATTGAGTTGACTGATGCCATTGCTGAGTTGGCAAAA AAACAAGCAGTTGACGCAATGCTGATGACTGGGGACAGTTACGACTGCGGAAAAGAAA ATGGGTTATATGCAAGCGTTTGTGAAGTATGGGCTGCGTAACCTAAAAGAGGGGGCG AAGTCCCGTAAAGGGATTGAGAAGCTGTTAAGCGAATAATGAAAATCTGACCGGATG TAACGGTTGATAAGAAAATTATAACGGCAGTGAAGATTAGCGGCGAAAAGTAATTTGT TGCGAATTTTCTGCCGTTGTTTTATATAAAACAATCAGAATAACAACGAGTTAGCAA CAGGATTATCGTCAAAGTTTTCCAGGATTTTCTTGTTCAGAGCGGATTGGTAAG ACAATTAGCTTCTGAATTTTTCGGGTTTAGCGCGAGTGGGTAACACTCGTCACATCG TAGGCATGCATGCAGTGCTCTGGTAGCTGTAAAGCCAGGGGCGGTAGCGTGCAATTA TACCTCTATTAATCAAACCTGAGAGCCGCTTATTTACACAGCATGCTCTGAAGTAATAT GGAATAAATTAAGTAAAATACTTGTACTGGTGGCGCAGGATTTATTGGTCTGCT GTAGTTTCGTACATTATAAATGATACGCAGGATAGTGTGTTAATGTCGATAAAATTA ACGTACGCCGAAACCTGGAATCACTTGCAGATGTTTCTGATTCTGAACGCTATTTT TTTGAACATGCGGATATTTGTGATGCAGCTGCAATGGCACGGATTTTTGCTCAGCAT CAGCCGGATGCAGTGATGCACCTGGCAGCTGAAAGCCATGTTGACCGTTCAATTACA GGCCCTGCGGCATTTATTGAAACCAATATTGTTGGTACTTATGTCCTTTTAGAAGCG GCTCGGAATTACTGGTCTGCACCTTATGGCGACAAGAAAAACAGCTTCCGTTTTTCAT CATATTTCTACTGACGAAGTCTATGGTGATTTGCCCTCATCTGACGAGGTAAATAAT AAAGAAGGATTACCCTTATTTACTGAGACGACAGCCTACGCACCAAGCAGCCCTTAT TCTGCATCAAAGCGTCCAGCGATCATTTAGTCCGTGCGTGGAACGTACCTATGGT TTACCGACCATTGTGACTAATTGCTCTAACAATATGGTCCCTTATCATTTCCCGGAA AAATTGATTCCATTGGTTATTCTGAATGCTCTGGAAGGTAAGGATTACCTATTTAT GGAAAAGGCGATCAAATTCGCGACTGGCTGTATGTTGAAGATCATGCGCGTGCGTTA TATAACCGTCGTAACCGAAGGTAAGCGGGTAAAACCTTATAACATTTGGTGGACACAAC GAAAAGAAAACATCGATGTAGTGCTCACTATTTGTGATTTGTTGGATGAGATTGTC CCGAAAGAGAAATCTTACCAGGAGCAAATTAATGTTGCGGATCGTCCGGGACAC GATCGACGTTATGCGATTGATGCTGAGAAGATTGGTTCGCGAATTTGGGATGGAAACCA CAGGAAACGTTTGGAGAGCGGGATTTCGTAACCACTGTGGAATGGTATCTGTCCAATACA AAATGGGTTGATAATGTGAAAAGTGGTGCCTATCAATCGTGGATTGAACAGAACTAT GAGGGCCGCCACTAATGAATATCCTCCTTTTTGGCAAAACAGGGCAGGTTGGTTGGG AACTACAGCGTGCTCTGGCACCTCTGGGTAATTTGATTGCTCTTGTGTTCACTCCA CTGATTACTGTGGTGATTTTAGTAACCCCTGAAGGTGTGGCTGAAAACCGTTAGAAGCA TTCGGCCTGATATTATTGTCAACGCAGCCGCTCACACCGCAGTAGACAAAGCAGAAT CAGAACCAGGAGTTTGACAATTAATGAACGCGACGAGTGTGGAAGCGATCGCGAAAAG CAGCCAATGAAGTCGGCGCTTGGGTTATTTCACTACTCTACTGACTACGTATTTCCGG GGACCGGTGAAATACCATGGCAGGAGGAGGATGCAACCGCACCGCTAAATGTTTACG	5

Description	SEQUENCE	SEQ ID NO.
	GTGAAACCAAGTTAGCAGGAGAAAAAGCATTACAAGAGCATTGTGCGAAGCACCTTA TTTTCCGGACCAGCTGGGTCTATGCAGGTAAAGGAAAATAACTTCGCCAAAACGATGT TGCGTCTGGCAAAAGAGCGTGAAGAATTAGCCGTTATTAATGATCAGTTTGGTGC GC CAACTGGCGCAGAGTTGCTGGCTGATTGTACGGCACATGCCATTCGTGTGGCACTGA ATAAACCGGAAGTCGCAGGTTTGTACCATCTGGTAGCCAGTGGTACCACAACCTGGC ACGATTATGCTGCGCTGGTTTTTGAAGAGGCGCGCAAAGCAGGCATTCGCCCTTGCAC TCAACAAGCTCAACGCAGTACCAACAACAGTCTATCCTACACCAGCTCGTCGTCCAC ATAACTCTCGCCTTAATACAGAAAAATTTAGCAGAACTTTGCGCTTGTCTTGCCTG ACTGGCAGGTTGGTGTGAAACGCATGCTCAACGAATTATTTACGACTACAGCAATTT AATAGTTTTTGCATCTTGTTCGTGATGGTGGAAACAAGATGAATTTAAAGGAATGATG GAATGAAAACCGCTAAAGGTATTATTTTAGCGGGTGGTTCGTGACACGTCTTTATC CTGTGACTATGGCTGTCAGTAAACAGCTGTTACCGATTTATGATAAACCGATGATCT ATTACCCGCTCTCTACACTGATGTTGGCGGGTATTCGCGATATTTGATTATCAGCA CGCCACAGGATACTCCTCGTTTTCAACAACCTGCTGGGTGATGGGAGCCAGTGGGGGC TAAATCTTCACTACAAAAGTGAACCCGAGTCCGGATGGTCTTGCAGGCATTTATCA TCGGTGAAGAGTTTATCGGTGGTGTGATTGTGCTTTGGTACTTGGTGATAATATCT TCTACGGTCACGACCTGCCTAAGTTAATGGATGCCGCTGTTAACAAAGAAAAGTGGTG CAACGGTATTTGCCTATCACGTTAATGATCCTGAACGCTATGGTGTGTTGAGTTTG ATAAAAACGGTACGGCAATTAGCCTCGAAGAAAAACCGCTACAACCAAAAAGTAAT ATGCAGTAACCGGGCTTTATTTCTATGATAACTACGTTGTGGAAAATGGCGAAAAATC TTAAGCCTTCTGCCC GCGGTGAACTGGAAATTACC GATATTAACCGTATTTATATGG AACAGGGGCATTTATCTGTTGCCATGATGGGACGTGGTTATGCATGGCTGGACACGG GGACACATCAGAGTCTTATTGAAGCAAGCAACTTCATTGCCACCATTGAAGAGCGCC AGGGACTAAAGTTTTCTGCCAGAAAGAAATGCTTATCGTAAAGGATTTATTGACG CAGAGCAGGTTAAGGTATTAGCCGAACCGCTGAAGAAAAACGCTTATGGTCAGTATT TGCTGAAAATGATTAAGGTTAGTAATAAAATGAATGTTATTTAAAACAGAAATTTCCA GACGTA CTGATTTTTGAACCGAAAAGTTTTTGGTGACGAGCGCGGTTTTCTTTTTCGAA AGCTATAACCAGAGGGTTTTTGGAGAAAGCTGTAGGTCGCAAAGTTGAGTTTGTTCAG GATAACCATTCTAAATCGAGAAAAGGAGTATTGCGGGGATTGCATPATCAATTAGAG CCGTATGCGCAAGCAAACTTGTGCGTTGCATTGAGGGTGAAGTATTTGATATTGCT GTAGATATACGGAAGTCATCTCCATTTTTTGGTAAATGGGTGGTGTAAACATTATCC GCTGAAAATAAACGTC AATTATGGATCCCTGAAGGGTTTTGCTCATGGTTTTGTGGTG ATTAGTGATACTGCGGAATTTGTCTATAAAAACGAACAATTATTACAGTCAACAAGCA GAGCGAAGCATAATTTTTGATGATAAAGACTTAGGGATTGCTTGGCCATTGAATACT CATTATATTCTTTAGAAAAGATTTAAATGCGCCAACATTTAAGAAAATATCGAGT AATGAGTATTTTAAATGAGTTAATCAAAAACAGTTTTTGGAACCTTTGCGGGTATG TACTTCCAGCTATTGTGACACTACCAGCTTTGGGTATTATGGGGCGAAAATTAGGCC CAGAATTATTTGGTGTATTCACTTTGGCATTAGCTGTTGTGGGTATGCAAGCATTT TTGATGCAGGCCTTACTCGCGCAGTGATACGAGAAGTCGCAATTGAAAAAGATAATG AAGAAAATAAGTTGAAAATTATTTCTTCAGCGACAGTTGTAATTTATTTATTTGAGTT TGGCCGCTCACTCTTATTATTTTTTTTTTAGTGGTCATATCGCATTGCTACTGAACA TTAGTGAGACTTTTTTTTATAATGTAAGTGTCTCGCTTAAAATTTCTCGCAGCATCCA TACCATTATTTTTGATTACTCAAATATGGTTGTCAATTTTAGAAGGTGAAGAAAAGAT TTGGTTTACTTAATATCTACAAATCAATTACGGGAGTGATATTAGCAATCTCACC GG CATTATTTATACTTATTAACCCCTCTTTGATGTATGCGATAATAGGCTTAGTTCTAG CAAGGTTTTTATGTTTTATTTTTGGCTTTTTATAATTTGTACAGATAAAGTGCTTAAAG CTAAACTAACAATCGATATACCAACAATTTAAAGATTGTTTATGTTTCGGTGGTTGGA TTACAGTAAGTAATATCATCAGCCCTGTGCTATCATATTTTGATAGGTTTATTGTTT	

Description	SEQUENCE	SEQ ID NO.
	<p>CAAATCAACTTGGGGCTGCTAATGTTGCTTTTTTATACTGCACCATCAGAAATTATTT CTCGGCTTAGTATAAATCCAGGTGCGTTTTCAAGAGCCTTATTTCCAAGATTAGCTA ATGCAAATAAATCCGCTGAAAAGATATAAAAACGAAAAGATTAATTACAATTTCACTTT TAATAATCATCACCCCTATTTTTTTGTATTGGCGTGTTATTTTCAGAGAAGATAATGG TTTTATGGATGGGGGCATCATTTTTTTGGTGAGCCTGGTTTGGTATTATCAATATTAC TGATTGGCTTTATTTTTAATGGATTGGCACAAGTACCATTTGCCAGTATTCAATCCC GAGGTCATGCTAAGATAACTGCATTTGTTTCATCTCTTAGAGTTGTTTCCTTATTTAT TACTTTTTATTTTACCTCATAAAAGCACATGGGGTTGTTGGCGCGGGTATTGCGTGGT CAGTGAGGATGATAGTAGATTATATAGCATTAAGTCTTTTGGACGGTAAGTATATTA AATAATAAAATTCAAAATGCAAGTTAATAACTCATGGCTTTATTTGGGTAGGTGACA ATTTATAATGATATATATATTAACCTTTAACTCTTCTCTAGTTATAGCCATAATGTT TTCTCTTCTCGGCACAAAAGTAGGATCACATCTCCATTACCTTTGCATTTTTTACC ATGGTTACTAACTTTAATTGTGCGGATAAGTAATTACGATCAATTTTACGAGTTTAA TGAAAGAAGCTTTTACTCTTTGTTGATTTGGTTTACAGTTATTTTTATATTTTTATTT CATAGGGGAAGTGGTTAATTATAAACGTGAAAATATAAATGTTTATTATGGTCTTTC ACATATTAATATGAATGTAAAAAATATTGGATCATTTGTCATCCCAATTTCAATTATA TACCATTTTTCGAAATATATATGGTTGGTATGGGGGAGCAGATGGATTCTTTCTCAA TTTACGTCTTGCAAATACATTGGAGGGCTATACGGGTAAAAAATTTATCTTAATGCC TGCTGTATATCCTCTAATGATGGCTATGTTTCGCAATTGTTTGTCTAACAAAAACTTC CAAATTAATAAATACTCCATTTATTTCTGGATGTTTTTGTATTGTATTGGCACAAAT GGGAAAATTTTTCAATATTAACGCCAATATTGACATATTTAATTTATTTATGACTTCAA ACATAGATTA AAAAGTAAAAAAAACAATAAAGTTTACATTTGTTGATAAATTATATTAGC TTTAACTTTGCATTTTACACGTATGGCTGAGAATGACCACTCAACATTTTTATCTAT TTTAGGGCTCTATATTTATTACCAATAAATTGCTTTAGGCCAGTTGAATGAAGTAAA TAGTAGTCATTTTGGTGAGTATACGTTTAGATTATATATGCTATAACTAATAAAAT TGGCCTTATTAAGAATTGCCAGTAAATACTATTCTTGACTATTACATACGTTCCCTGT ACCAACAAATGTATATACTGCACTTCAACCATTTTACCAGGATTTTGGTTATACTGG CATCATATTTGGAGCAGTATTATACGGACTAATATATGTGAGTTTATACACGGCCGG TGTTTCGTGGAAATAATACACAGGCATTACTGATTTACGCATTGTTTTAGTTAGCAG TGCAACGGCTTTCTTCGCTGAAACGCTAGTAACGAATTTAGCTGGAAATGTGATGTT AGTATTATGTACCATCTTACTATGGCGATTTACAGTAATATGCAAACAGTACAGTA ACCATTCTAATGGCCACCTACAATGGCGAGGCCTTCATCAAAAATCAGATTTTGTCA CTACAACAACAACATTTTCTAACTGGCGGTTATTTATTTCAGGATGATGGGTCTACA GACAATACTATATCTATAATAAAAAAATCTCCAAAAATCTGACTCCAGAATTCGGCTA GTTGATGATAATTTGAAAGGTCAAGGTGCAGGAAAAAATTTTTTATCGCTGATAAAG TACAGCGAGACAGATTATAACAATTTATTGTGACCAAGATGATATTTGGTTAGAAAAC AAAATATTTGAATTAGTAAAGTATGCAAATGAAATTAATTTGAATGTATCAGATGCC CCTTCGCTAGTTTATGCTGATGGCTATGCTTATATGGATGGTGAGGGTACAATCGAT TTTTCTGGGATATCTAACAATCATGCTGATCAATTAAGGATTTTCTTTTTTTTAAAT GGTGGATAACCAAGGATGTTCTATTATGTTCAATCGTGCAATGACCAAATTTCTTCTG AATTATCGAGGATTTGTATATCTACATGACGATATCACAACATFAGCTGCATACGCT CTTGGTAAAGTTTATTTTCTCCCGAAATACCTTATGTTATATAGACAGCACACGAAT GCGGTAACCTGGTATCAAAACATTCGCAATGGATTGACTTCTAAATTTAAATCACCA GTAAACTATCTTTTATCACGAAAACATTATCAGGTAAAAAATCTTTTTTTGAATGT AACAGCTCTATCTTATCAGAGACGAATAAAAAAGTTTTTTTTGGATTTTATTTCAATTT TGTGAATCAAATAATAAATTTACAGATTTTTTTTAAAGTTATGGCGAGGTGGGTTTAGA TTAAATAACAGTAGAACTAAATTTATTTAAATTTCTTAATACGGAGAAAATTTAGC GAATGATTTCAATACTTACACCTACTTTTAAATCGGCAACATACTTTATCAAGGCTAT</p>	

Description	SEQUENCE	SEQ ID NO.
	TCAATTCTCTTATATTACAACTGATAAAGATTTTGAGTGGATAATAATTGATGATG GTAGTATAGATGCAACAGCGGTACTTGTAGAAGATTTTAGAAAAAATGTGATTTTG ACTTGATTTATTGCTATCAGGAAAAATAATGGTAAGCCCATGGCTTTAAACGCTGGTG TTAAGCTTGTAGAGGCGATTATATCTTTATTGTTGACAGTGATGATGCACTAACTC CCGATGCCATAAAATTAATTAAGAATCAATACATGATTGCTTATCTGAGAAGGAAA GTTTCAGCGGAGTCGGTTTTAGAAAAGCATATATAAAAAGGGGGGATTTATTGGTAATG ATTTAAATAATTCTTCAGAACATATATACTATTTAAATGCGACTGAGATTAGCAATT TAATAAATGGTGATGTTGCATATTGTTTTAAAAAAGAAAAGTTTGGTAAAAAATCCAT TCCCCCGTATAGAAGATGAAAAATTTGTTCCAGAATTATATATTTGGAATAAAATAA CTGACAAGGCGAAGATTGATTAAACATAAGCAAAGTTATATATCTTTGTGAGTATC TTGATGATGGTCTTTCTAAAAATTTCCATAACCAGCTTAAAAAATACCCAAAGGGGT TTAAGATTTATTACAAAGATCAAAGAAAACGAGAGAAAACCTTATATAAAAAAACAA AGATGCTAATTAGATATTTGCAATGTTGTTATTATGAGAAAATAAAATGAAAATACT ATTTGTCATTACAGGTTTAGGCCCTTGGAGGTGCTGAGAAGCAGGTTTGTCTTTTAGC TGATAAATTAAGTTTAAAGCGGGCACCATGTAAAGATTATTTCACTTGGACATATGTC TAATAATAAAGTCTTTCTAGCGAAAATAATGTTAATGTCATTAATGTAATAATGTC AAAAAACATTTCTGGAGTTATAAAAGGTTGTGTCAGAATTAGAGATGTTATAGCTAA TTTCAAACCAGACATTGTACACAGTCATATGTTTCATGCAAACATTTACTAGATT GTCTGTAATTGGAATCAAAAACAGACCTGGTATTATATCAACTGCACATAATAAAAA TGAAGGTGGGTATTTGAGAATGCTCACATATAGAATAACCGATTGTTAAGTGATTG TTGTACAAATGTTAGCAAAGAAGCAGTGGATGAGTTTTTACGGATAAAAAGCCTTTAA TCCCGCTAAAGCAATTAATGATAATGGGATAGATACCAATAAAATTTAAATTTGA TTTATTGGCAAGGAGGGAAATTCGAGACGGTATTAATATAAAAAATGATGATATATT ATTACTTGCTGCAGGTCGTTTAAACGTTAGCTAAAGATTATCCTAATTTATTGAATGC AATGACTCTGCTTCTGAACACTTTAACTTATTATTATTGGTGATGGTGAATGCG TGACGAAATTAATATGCTTATAAAAAAATGCAATTATCTAATAGGGTGTCTTGT GGGAGTTAAAAAATATTGCTCCCTATTTTTCTGCATGTGATATTTTTGTTCTCTC TTCTCGTTGGGAAGGATTTGGATTAGTCGTGGCAGAAGCTATGTCATGTGAGCGAAT TGTTGTTGGCACGGATTGAGGGGGAGTAAGAGAAGTTATTGGTGACGATGATTTTCT TGTACCCATATCTGATTCAACACAACCTTGAAGCAAAATGAAAAATGTCCTTTGAG CCAGATACGTGATCACATTGGTTTTCGGAATCGTGAGCGTATTTTAAAAAATTTCTC AATAGATACTATTATTATGCAAGTGGCAAGAACTCTATGGAACATAAATTTGCTCAA ACATGAAAGGTAGATTTATATTTGGAACGTGCTTTTTGTTTGAATTTAATTCATCT CAATTGAGATTTTTGTATTTCAAAAATACCATCATAGCTAACGATGATTGGTATTTA TTTTAAGATGCTTTCTATAAATATATTGACGTTTTTAATGCGCCGAAACGATTGGGC TGGGAACAGAGAAGTAAACTGTTTTGAGAATGAAGAGTTTTTGAAGTGTATGGA TATTAATAAATTGATCCAGTGAATTAATTTTATAATAAATCAAGATTTAATGTTAA TAAATGATAATCTTTTCTGACACTCATATTAATTATGAGTGGTACGTTTGGTAAACG GTAAACTATTATATGACAGCTAGAACAACATAAAGTTTTGCACTTACAATTACTCCCA CTCTTAAGTGGCGTTCAAAGGGTAAACATAAAGCAAAATAGTGCGTTATATACTGAT TATGATTATACACTAGTTTGTCTAAAAAAGGTCCACTAACAAAAGCATGCTGGAA TATGATGTCGATTGTCATTGTATCCCCGAACCTACGAGAGAAATACCGTAAAGAAT GATTTTAAAGCATTGTTCAAGCTTTATAAGTTTATAAAAAAAGAAAAATTTGACATT GTGCATACACATTCTTCAAAAACAGGTATTTTGGGGCGAGTTGCTGCCAAATTAGCA CGTGTGGAAAGGTGATCCACACTGTACATGGTTTTTTCTTTTCCAGCCGCATCTAGT AAAAAAAGTTATTACCTTTATTTTTTTCATGGAATGGATAGCAAAGTTCTTTACGGAT AAGTTAATCGTCTTGAATGTAGATGATGAATATATAGCAATAAACAAATTTAAATTC AAGCGGGATAAAGTTTTTTTTAATTCCTAATGGAGTAGACACTGATAAGTTTTCTCCT	

Description	SEQUENCE	SEQ ID NO.
	<p>TTAGAAAATAAAATTTATAGTAGCACCTTGAATCTAGTAATGGTTGGTAGATTATCC AAGCAAAAAGATCCTGAGACATTATTGCTTGCTGTTGAAAAACTGCTGAATGAAAAT GTTAATGTTAAGCTGACACTTGTAGGAGATGGTGAACAAAAAGAACAGTTAGAAAAGC AGGTTCAAACGGCAAGATGGACGTATAATTTTTTCATGGATGGTCAGATAACATTTGTT AATATTTTTAAAAGTTAATGATCTTTTTATATTACCTTCTCTTTGGGAGGGTATGCCA TTAGCAATTTTAGAAGCATTGAGCTGTGGACTTCCATGTATAGTCACTAATATTTCCA GGTAATAATAGCTTAATAGAAGATGGCTATAATGGTTGTTTGTGTTGAAATTAGAGAT TGTCAGTTATTATCTCAAAAAATCATGTATATGTTGGTAAGCCGAACTGATTGCA CAGCAATCTACCAATGCACGATCATTTATTTCTGAAAAATTTATGGATTAGTTAAAAAG AATAATAAGGTGAGACAGCTATATGATAATTAATGAAACCAGAAAAGTTAAAAAAGA ACAGGTTTTTCAAAGTAAAATAAAAATTACAGTTTTTTTTATTGCAATGATTAACGTA ACATCTGCATTACATTCAAGCCGCACAACCCCGGGTGACCACCCCTGACAGGAGTA ACAATGTCAAAGCAACAGATCGGCGTCGTCGGTATGGCAGTGATGGGACGCAACCT CGCGCTCAACATCGAAAGCCGTGGTTATACCGTCTCTATTTTCAACCGTTCCTCGTGA AAAGACGGAAGAAGTTATTGCCGAAAATCCAGGCAAGAAAAGTTGTTTCTTACTATAC GGTGAAGAGTTTCGTTGAATCTCTTGAACCGCTCGTCGCATCCTGTTAATGGTTAA AGCAGGTGCAGGCACGGATGCTGCTATTGATTCCCTGAAACCATATCTCGATAAAGG CGATATCATCATTGATGGTGGTAATACCTTCTTCCAGGACACCATTTCGTCGTAACCG CGAGCTTTCTGCACAAGGCTTTAACTTCATCGGTACGGGTGTTTCCGGTGGTGAAGA GGGCGCGCTGAAAGGACCTTCTATCATGCCTGGTGGGCGAGAAAGAGGCCATGAACT GGTTGCTCCTATCCTGACCAAAAATCGCCGCCGTGGCTGAAGATGGTGAACCATGCCT TACCTATATTGGTGCCGATGGCGCAGGTCACCTATGTGAAGATGGTTCACAACGGTAT TGAATACGGTGATATGCAACTGATTGCTGAAGCCTATTCTCTGCTGAAAGGTGGTCT GAATCTCTTAACGAAGAAGTGGCACAACCTTTACCAGTGAATAACGGTGAACCT GAGCAGTTACCTGATCGACATCACTAAAGACATCTTACCACAAAAAGATGAAGACGG TAACTACCTGGTTGATGTGATCCTGGATGAAGCAGCAAAACAAAGGTACGGGTAAATG GACCAGTCAGAGCGCGCTGGATCTCGGTGAGCCACTGTCGCTGATTACTGAGTCTGT GTTTGCACGCTACATCTCTTCACTAAAAGATCAGCGCGTGGCTGCGTCTAAAGTACT GTCGGGTCCACAAGCGCAGCCAGCAGCGACAAAGCAGAGTTCAATTGAAAAAGTTTCG CCGTGCGCTTTATCTGGGTAAGATTGTTTCTTACGCGCAGGGCTTCTCTCAGCTGCG TGCTGCGTCTGAAGAGTACAACCTGGGATCTGAACTACGGTGAATCGCGAAGATTTT CCGTGCTGGCTGCATCATCCGTGCGCAGTTCTTGCAGAAAAATCACCGATGCTTATGC CGAAAATCCGCAGATCGCTAACCTGCTGCTGGCTCCGTACTTCAAGCAAATGCCCGA TGACTACCAGCAGGCTCTGCGTGATGTCGTTGCTTATGCAGTACAGAACGGTATCCC GGTTCCGACCTTCGCCGCTGCGGTTGCCTATTACGATAGCTACCGTGCCGCTGTTCT GCCTGCGAACCTGATCCAGGCACAGCGTGACTATTTCCGTGCACATACTTATAAGCG CATTGATAAAGAAGGTGTGTTCCATACTGAATGGCTGGATTGA</p>	
<p>PglB oligo- saccharyl transferase</p>	<p>MLKKEYLKNPYLVLFAMI I LAYVFSVFCRFYVWVWASEFNEYFFNNQLMI I SNDGYA FAEGARDMIAGFHQPNDLSYYGSSLSALTYWLYKITPFSFESI I LYMSTFLSSLVVI PTILLANEYKRPLMGFVAALLASIANSYNRTMSGYDMDLVIIVLPMFILLFFMVRM ILKKDFFSLIALPLFIGIYLWYWPSSYTLNVALIGLFLIYTLIFHRKEKIFYIAVIL SSLTLSNIAWFYQSAL I VILFALFALEQKRLNFMI I GILGSATLIFLILSGGVDPI L YQLKFYIFRSDESANLTQGFMYFNVNQTIQEVENVDLSEFMRRISGSEIVFLSFLG FVWLLRKHKSMIMALPILVLGFLALKGGLRFTIYSVPVMALGFGFLLSEFKAIMVKK YSQLTSNVCIVFATILTLAPVFIHIYNYKAPT VFSQNEASLLNQLKNIANREDYVVT WWDYGYPVRYSDVKTLLVDGGKHLGKDNFFPSPFALS KDEQAAANMARLSVEYTEKSF YAPQNDILKTDILQAMMKDYNQSNVDLFLASLSKPDFKIDTPKTRDIYLYMPARMSL IFSTVASFSFINLDTGVLDKPFSTAYPLDVKNGEIYLSNGVVLSDDFRSFKIGDN</p>	<p>6</p>

Description	SEQUENCE	SEQ ID NO.
	VVSVNSIVEINSIKQGEYKITPIDDKAQFYIFYLKDSAI P YAQFILMDKTMFNSAYV QMFFLGN YDKNLFDLVINSRDAKVFKLKI	

Examples

The following examples of the invention are to further illustrate the nature of the invention. It should be understood that the following examples do not limit the invention and that the scope of the invention is to be determined by the appended claims.

A bioconjugation system in *E. coli* has been developed recently, in which the antigen polysaccharide and the carrier protein are both synthesized *in vivo* and subsequently conjugated *in vivo* through the activities of the oligosaccharyl transferase PglB, a *Campylobacter jejuni* enzyme, expressed in *E. coli* (Wacker et al., Proc. Nat. Acad. Sci. (2006) v. 103, pp. 7088-93). This N-linked protein glycosylation system is capable of the transfer of diverse polysaccharides to a carrier protein, allowing for methods to purify the bioconjugate from bacteria wherein it is expressed. Bioconjugation has been used successfully to produce conjugate polysaccharide for an *E. coli* four-valent O-antigen candidate vaccine (Poolman and Wacker, J. Infect. Dis. (2016) v.213(1), pp. 6-13; WO 2015/124769; WO 2017/035181). A composition comprising 10 bioconjugates (O1A, O2, O4, O6A, O8, O15, O16, O18A, O25B and O75, the composition being referred to as ExPEC10V) has been described and is in clinical trials (e.g., WO2020/191082A1). Each of the bioconjugates are produced by a separate production strain, which show O-serotype dependent yield variation. For O-antigen production strains of several O-serotypes, yield improvements could be obtained by expressing variants of the *C. jejuni* glycosyl transferase PglB with modified substrate specificities (see e.g. WO 2016/107818, WO 2016/107819). However, for the O18 O-serotype, that displayed the lowest yields of bioconjugate production amongst the ten serotypes of which bioconjugates were made for the ExPEC10V composition, the use of variants of the *C. jejuni* PglB protein and the use of alternative PglB homologs did not lead to yield improvements. Additionally, further platform modifications aimed to increase O18 bioconjugation yield, were not successful in reaching this goal. Among these modifications were the overexpression of WecA, a protein that initiates O-unit biosynthesis by catalyzing the transfer of *N*-acetylglucosamine (GlcNAc)-1-phosphate onto undecaprenyl phosphate (Und-P) to form Und-P-P-GlcNAc. Additionally, the replacement the native Wzz O-antigen chain length regulator present in the *E. coli* K-12 bioconjugation platform strain for the O-antigen chain length regulator of other gram-negative bacterial species, leading to increased O18A O-antigen chain lengths, did not result in a significantly increased product yield.

Example 1: O18 bioconjugate production strain with improved yield

We did however obtain strains that had increased O18 bioconjugate product yields, and found that the Wzy O-antigen polymerase in those strains had amino acid mutations as compared to Wzy in the existing O18 bioconjugate production strain (that had a Wzy O-antigen polymerase having SEQ ID NO: 1). Based on this, we created a novel production strain for O18 bioconjugates, which is otherwise identical as except for three amino acid mutations in its Wzy O-antigen polymerase compared to the previously described (see WO 2020/191082) O18 bioconjugate production strain. In particular, the Wzy O-antigen polymerase in the previously described strain had amino acids threonine (T), methionine (M), and valine (V) at positions 199, 377, and 395, respectively (i.e., the Wzy O-antigen polymerase of that previously described strain is given in SEQ ID NO: 1), while the new production strain had amino acids isoleucine (I), lysine (K), and alanine (A) at those respective positions.

The yield of the O18 bioconjugate in the filtered periplasmic fraction of a 200L bioreactor run after osmotic shock (i.e. at an early point in the process where a reasonable quantification of yield is possible) was about 2.4 times higher for the new strain versus the previously described strain.

The occupancy of glycosylation sites of an EPA carrier protein that had four N-glycosylation consensus sequences was increased in the new strain versus the previously described strain, i.e. the new strain induced more di-, tri-, and tetra-glycosylated EPA carrier protein (e.g. Fig. 1).

Example 2: Construction of modified Wzy O-antigen polymerases

Next we undertook a mutagenesis study of the Wzy O-antigen polymerase amino acid sequence and we identified specific combinations of amino acid substitutions in these three positions in the Wzy O-antigen polymerase sequence of SEQ ID NO: 1 that had an effect on yield and glycosylation pattern of the O18 bioconjugates.

Various combinations of amino acid substitutions in one or more of the positions 199, 377 and 395 in the amino acid sequence of SEQ ID NO: 1 of the Wzy O-antigen polymerase were produced using site directed mutagenesis using standard procedures. The various combinations that were generated are indicated in Table 3.

Example 3: Production of O-antigen polysaccharide using the modified Wzy O-antigen polymerase

The *wzy* gene present in the *rfb* cluster from *E. coli* serotype O18A (example provided as SEQ ID NO: 5) that had been inserted into the chromosome of *E. coli* K-12 bioconjugate production strain W3110, was replaced by gene variants coding for modified Wzy O-antigen polymerases having SEQ ID NO: 1 with the mutations as indicated in Table 3, by homologous recombination-based genetic modification techniques. In addition to the *rfb* cluster from *E. coli* serotype O18A, the *E. coli* bioconjugate production strain W3110 further comprised nucleic acid encoding EPA carrier protein (having SEQ ID NO: 3), and nucleic acid encoding the oligosaccharyl transferase PglB (having SEQ ID NO: 6). O18A polysaccharide bioconjugates were produced in shake flask cultures and extracted using osmotic shock, as previously described e.g. in WO 2020/191082.

Example 4: Characterization O18- bioconjugates

Periplasmic extracts from shake flask cultures of *E. coli* K-12 bioconjugate production strain W3110 containing Wzy variants (with mutations as indicated in Table 3) that were induced for O18A polysaccharide bioconjugate expression, were subjected to a capillary electrophoresis immunoassay using O18A specific monoclonal antibodies for immunodetection of bioconjugates. Relative quantitation was performed for each sample based on signal intensity of the peaks corresponding to sEPA, monoglycosylated EPA and higher forms of glycosylated EPA (di-/tri-/tetra-glycosylated EPA) as determined by MW relative to the total product signal (Table 3).

Table 3. Wild-type and variant Wzy O antigen polymerases with amino acid substitutions in one or more of positions 199, 377 and 395 of SEQ ID NO: 1 as indicated and their effect on glycosylation pattern of the O18 bioconjugates. Variants leading to improved glycosylation pattern are indicated in bold.

Construct ID	Wzy amino acid position			Percentage of each subform within total product		
	199	377	395	sEPA	Mono	Di/Tri/Tetra
Previously described production strain (Wzy having SEQ ID NO:1)	T	M	V	31%	45%	24%
New production strain	I	K	A	10%	34%	57%
Variant 1	I	M	V	26%	45%	29%
Variant 2	T	K	V	6%	24%	71%
Variant 3	T	M	A	21%	41%	38%
Variant 4	T	K	A	8%	27%	65%
Variant 5	I	K	V	10%	30%	61%
Variant 6	I	M	A	6%	34%	60%

Example 5: Production O18 bioconjugate with new production strain, and of ExPEC9V and ExPEC10V multivalent products that have immunogenic activity

The new strain for production of O18A bioconjugates was used to produce O18A bioconjugate, O18A bioconjugate was extracted from the periplasm after osmotic shock, subjected to chromatography to remove host cell proteins, and the extracted bioconjugate was used to prepare a pharmaceutical composition comprising this O18A bioconjugate as a drug substance, essentially as described in WO 2020/191082 (example 8 therein).

The new O18A drug substance was also mixed with drug substances of other bioconjugates of *E. coli* O-antigens O1A, O2, O4(glc+), O6A, O15, O16, O25B, and O75, and in some cases also including O8, to obtain multivalent (9-valent, respectively 10-valent) drug products. These drug products when administered to rabbits induced antibodies against the *E. coli* serotypes of which O-antigens were present in the compositions. Thus, the bioconjugates and compositions (obtained) according to (methods of) the invention were demonstrated to be suitable to induce immune responses against *E. coli*.

CLAIMS

1. A gram-negative bacterial host cell comprising:
- 5 (a) a carrier protein comprising at least one glycosylation consensus sequence;
(b) an *E. coli* O18 *rfb* locus; and,
(c) an oligosaccharyltransferase;
- wherein the cell comprises a polypeptide having Wzy O-antigen polymerase activity, which polypeptide comprises an amino acid sequence with at least 95% identity with SEQ ID NO:
- 10 1, wherein the amino acid sequence comprises:
- i) isoleucine at a position that corresponds to position 199 in SEQ ID NO: 1, lysine at a position that corresponds to position 377 in SEQ ID NO: 1, and alanine at a position that corresponds to position 395 in SEQ ID NO: 1;
- ii) threonine at a position that corresponds to position 199 in SEQ ID NO: 1, lysine at a position that corresponds to position 377 in SEQ ID NO: 1, and valine at a position that corresponds to position 395 in SEQ ID NO: 1;
- 15 iii) threonine at a position that corresponds to position 199 in SEQ ID NO: 1, lysine at a position that corresponds to position 377 in SEQ ID NO: 1, and alanine at a position that corresponds to position 395 in SEQ ID NO: 1;
- iv) isoleucine at a position that corresponds to position 199 in SEQ ID NO: 1, lysine at a position that corresponds to position 377 in SEQ ID NO: 1, and valine at a position that corresponds to position 395 in SEQ ID NO: 1; or
- 20 v) isoleucine at a position that corresponds to position 199 in SEQ ID NO: 1, methionine at a position that corresponds to position 377 in SEQ ID NO: 1, and alanine at a position that corresponds to position 395 in SEQ ID NO: 1.
- 25
2. A host cell according to claim 1, wherein the polypeptide having Wzy O-antigen polymerase activity comprises the amino acid sequence of SEQ ID NO: 1, except that the amino acid sequence comprises:
- 30 i) isoleucine at a position that corresponds to position 199 in SEQ ID NO: 1, lysine at a position that corresponds to position 377 in SEQ ID NO: 1, and alanine at a position that corresponds to position 395 in SEQ ID NO: 1;
- ii) threonine at a position that corresponds to position 199 in SEQ ID NO: 1, lysine at a position that corresponds to position 377 in SEQ ID NO: 1, and valine at a position that corresponds to position 395 in SEQ ID NO: 1;
- 35 iii) threonine at a position that corresponds to position 199 in SEQ ID NO: 1, lysine at a position that corresponds to position 377 in SEQ ID NO: 1, and alanine at a position that corresponds to position 395 in SEQ ID NO: 1;

- iv) isoleucine at a position that corresponds to position 199 in SEQ ID NO: 1, lysine at a position that corresponds to position 377 in SEQ ID NO: 1, and valine at a position that corresponds to position 395 in SEQ ID NO: 1; or
- v) isoleucine at a position that corresponds to position 199 in SEQ ID NO: 1, methionine at a position that corresponds to position 377 in SEQ ID NO: 1, and alanine at a position that corresponds to position 395 in SEQ ID NO: 1.
- 5
3. A host cell according to claim 1 or 2, wherein the polypeptide having Wzy O-antigen polymerase activity comprises isoleucine at a position that corresponds to position 199 in SEQ ID NO: 1, lysine at a position that corresponds to position 377 in SEQ ID NO: 1, and alanine at a position that corresponds to position 395 in SEQ ID NO: 1.
- 10
4. A host cell according to any one of claims 1 - 3, wherein a polynucleotide or vector encoding the polypeptide having Wzy O-antigen polymerase activity is integrated into the genome of the host cell.
- 15
5. A host cell according to any one of claims 1 - 4, wherein the host cell is an *Escherichia coli* host cell.
- 20
6. A host cell according to claim 5, wherein the host cell is an *E. coli* K-12 strain, preferably strain W3110.
7. A host cell according to any one of claims 1 - 6, wherein at least one of:
- 25
- a) the oligosaccharyl transferase comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 6;
- b) the carrier protein comprises SEQ. ID NO. 3; and,
- c) the *E. coli* O18 *rfb* locus is an *rfb* locus of an *E. coli* strain having serotype O18A.
8. A host cell according to any one of claims 1 - 7, wherein the oligosaccharyl transferase comprises the amino acid sequence of SEQ ID NO: 6.
- 30
9. A host cell according to any one of claims 1 - 8, wherein the host cell comprises an *E. coli* O18 *rfb* locus with a nucleotide sequence encoding a Wzy O-antigen polymerase that encodes a polypeptide having Wzy O-antigen polymerase activity and having a sequence as defined in any one of claims 1 - 3.
- 35
10. A method for producing a bioconjugate of an *E. coli* O18 antigen polysaccharide conjugated to a carrier protein, the method comprising: culturing a host cell according to any one of claims 1 - 9 to produce the bioconjugate.

11. A method according to claim 10, further comprising recovery of the bioconjugate.
12. A method according to claim 11, further comprising formulating the recovered bioconjugate
5 into a pharmaceutical composition.
13. A method according to claim 12, further comprising adding one or more additional
bioconjugates of *E. coli* O-antigen polysaccharides conjugated to a carrier protein to the
pharmaceutical composition to obtain a multivalent bioconjugate composition.
- 10 14. A method according to claim 13, wherein the one or more additional bioconjugates comprise
at least one O-antigen polysaccharide selected from the group consisting of *E. coli* serotypes
O1, O2, O4, O6, O8, O15, O16, O25 and O75.
- 15 15. A method according to claim 14, wherein the multivalent bioconjugate composition
comprises:
- (i) the bioconjugate of an *E. coli* O18A antigen polysaccharide conjugated to a carrier
protein;
 - (ii) a bioconjugate of an *E. coli* O1A antigen polysaccharide conjugated to a carrier protein;
 - 20 (iii) a bioconjugate of an *E. coli* O2 antigen polysaccharide conjugated to a carrier protein;
 - (iv) a bioconjugate of an *E. coli* glucosylated O4 antigen polysaccharide conjugated to a
carrier protein;
 - (v) a bioconjugate of an *E. coli* O6A antigen polysaccharide conjugated to a carrier protein;
 - (vi) a bioconjugate of an *E. coli* O15 antigen polysaccharide conjugated to a carrier
25 protein;
 - (vii) a bioconjugate of an *E. coli* O16 antigen polysaccharide conjugated to a carrier
protein;
 - (viii) a bioconjugate of an *E. coli* O25B antigen polysaccharide conjugated to a carrier
protein; and,
 - 30 (ix) a bioconjugate of an *E. coli* O75 antigen polysaccharide conjugated to a carrier
protein,
- wherein preferably the carrier protein in each bioconjugate comprises SEQ ID NO: 3.
16. A method according to claim 15, wherein the multivalent bioconjugate composition further
35 comprises:
- (x) a bioconjugate of an *E. coli* O8 antigen polysaccharide conjugated to a carrier protein,
wherein preferably the carrier protein comprises SEQ ID NO: 3.

1/1




Fig. 1

INTERNATIONAL SEARCH REPORT

International application No
PCT/IB2022/053013

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K39/108 A61P13/02
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2020/191082 A1 (JANSSEN PHARMACEUTICALS INC [US]; GLAXOSMITHKLINE BIOLOGICALS SA [BE]) 24 September 2020 (2020-09-24) cited in the application Examples and claims -----	1-16
X	US 2016/244489 A1 (MASIGNANI VEGA [IT] ET AL) 25 August 2016 (2016-08-25) SEQ ID NO:5010 in claim 1; Table 1 -----	1, 2, 4, 5, 9
A	WO 01/66572 A2 (INST NAT SANTE RECH MED [FR]; BINGEN EDOUARD [FR] ET AL.) 13 September 2001 (2001-09-13) Sequence 1328, Example 6 and Figure 6 ----- -/--	1-16

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

7 September 2022

Date of mailing of the international search report

23/09/2022

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040,
 Fax: (+31-70) 340-3016

Authorized officer

Gómez Ortiz, Mariola

INTERNATIONAL SEARCH REPORT

International application No
PCT/IB2022/053013

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>Anonymous: "O18ab/O18ac family O-antigen polymerase [<i>Escherichia coli</i>] - Protein - NCBI", UniParc -UPI000E210611 , 10 July 2019 (2019-07-10), pages 1-1, XP055838858, Retrieved from the Internet: URL:https://www.ncbi.nlm.nih.gov/protein/WP_115766377 [retrieved on 2021-09-07] abstract</p>	1-16
A	<p>----- FRANCESCA MICOLI ET AL: "Glycoconjugate vaccines: current approaches towards faster vaccine design", EXPERT REVIEW OF VACCINES, vol. 18, no. 9, 31 August 2019 (2019-08-31), pages 881-895, XP055689605, GB ISSN: 1476-0584, DOI: 10.1080/14760584.2019.1657012 Figure 2, Item 4</p>	1-16
A	<p>----- DEBROY CHITRITA ET AL: "Detection of O antigens in <i>Escherichia coli</i>", ANIMAL HEALTH RESEARCH REVIEWS, CABI PUBLISHING, GB, vol. 12, no. 2, 1 December 2011 (2011-12-01), pages 169-185, XP009178866, ISSN: 1466-2523, DOI: 10.1017/S1466252311000193</p>	1-16
A	<p>----- AMIRREZA FARIDMOAYER ET AL: "Functional characterization of bacterial oligosaccharyltransferases involved in O-linked protein glycosylation", JOURNAL OF BACTERIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 189, no. 22, 21 September 2007 (2007-09-21), pages 8088-8098, XP008126816, ISSN: 0021-9193, DOI: 10.1128/JB.01318-07 abstract</p>	1-15

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB2022/053013

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
- a. forming part of the international application as filed:
- in the form of an Annex C/ST.25 text file.
 - on paper or in the form of an image file.
- b. furnished together with the international application under PCT Rule 13ter.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
- c. furnished subsequent to the international filing date for the purposes of international search only:
- in the form of an Annex C/ST.25 text file (Rule 13ter.1(a)).
 - on paper or in the form of an image file (Rule 13ter.1(b) and Administrative Instructions, Section 713).
2. In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/IB2022/053013

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 2020191082	A1	24-09-2020	AR 118388 A1	29-09-2021
			AU 2020240072 A1	28-10-2021
			CA 3134216 A1	24-09-2020
			CL 2021002426 A1	29-04-2022
			CN 113924112 A	11-01-2022
			CO 2021013823 A2	29-03-2022
			CR 20210522 A	17-12-2021
			EA 202192390 A1	03-12-2021
			EP 3941516 A1	26-01-2022
			IL 286394 A	31-10-2021
			JP 2022533883 A	27-07-2022
			KR 20210141586 A	23-11-2021
			MA 55364 A	26-01-2022
			PE 20212265 A1	30-11-2021
			SG 11202110301T A	28-10-2021
			TW 202102255 A	16-01-2021
			US 2020316184 A1	08-10-2020
			UY 38616 A	30-09-2020
			WO 2020191082 A1	24-09-2020

US 2016244489	A1	25-08-2016	AU 2006214064 A1	24-08-2006
			CA 2601924 A1	24-08-2006
			CY 1117732 T1	17-05-2017
			CY 1118149 T1	28-06-2017
			DK 1858920 T3	29-02-2016
			DK 2351772 T3	05-09-2016
			EP 1858920 A2	28-11-2007
			EP 2351772 A1	03-08-2011
			ES 2569654 T3	12-05-2016
			ES 2595363 T3	29-12-2016
			HU E027400 T2	28-10-2016
			HU E030881 T2	28-06-2017
			JP 2008529558 A	07-08-2008
			JP 2012152228 A	16-08-2012
			LT 2351772 T	10-10-2016
			MX 306302 B	19-12-2012
			NZ 561042 A	31-03-2011
			NZ 597685 A	20-12-2013
			NZ 597769 A	27-09-2013
			PL 1858920 T3	30-12-2016
			PL 2351772 T3	31-01-2017
			PT 2351772 T	22-09-2016
			SG 160329 A1	29-04-2010
			US 2008193470 A1	14-08-2008
			US 2014356389 A1	04-12-2014
			US 2016244489 A1	25-08-2016
			US 2018298064 A1	18-10-2018
WO 2006089264 A2	24-08-2006			

WO 0166572	A2	13-09-2001	CA 2402602 A1	13-09-2001
			EP 1328641 A2	23-07-2003
			JP 2004512817 A	30-04-2004
			WO 0166572 A2	13-09-2001
